WO2006045514A1 - 3-arylamino pyridine derivatives - Google Patents
3-arylamino pyridine derivatives Download PDFInfo
- Publication number
- WO2006045514A1 WO2006045514A1 PCT/EP2005/011257 EP2005011257W WO2006045514A1 WO 2006045514 A1 WO2006045514 A1 WO 2006045514A1 EP 2005011257 W EP2005011257 W EP 2005011257W WO 2006045514 A1 WO2006045514 A1 WO 2006045514A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fluoro
- alkyl
- phenylamino
- iodo
- isonicotinamide
- Prior art date
Links
- 0 *c1ccc(*(C2=C*CC=C2C(CCc2ccccc2)=O)=C)c(I)c1 Chemical compound *c1ccc(*(C2=C*CC=C2C(CCc2ccccc2)=O)=C)c(I)c1 0.000 description 8
- WAPGCTUUSKUXPT-UHFFFAOYSA-O CCONC(C(C(Nc(cc1)c(C)cc1Br)=C[NH2+]O)=CC=C)=O Chemical compound CCONC(C(C(Nc(cc1)c(C)cc1Br)=C[NH2+]O)=CC=C)=O WAPGCTUUSKUXPT-UHFFFAOYSA-O 0.000 description 1
- LZQFYHQGOPVSPZ-SECBINFHSA-N C[C@H](CNC(c1ccncc1Nc(ccc(I)c1)c1F)=O)O Chemical compound C[C@H](CNC(c1ccncc1Nc(ccc(I)c1)c1F)=O)O LZQFYHQGOPVSPZ-SECBINFHSA-N 0.000 description 1
- CPONMWDKPHGWME-GFCCVEGCSA-N Cc(cc(cc1)I)c1Nc(cncc1)c1C(NOC[C@@H](CO)O)=O Chemical compound Cc(cc(cc1)I)c1Nc(cncc1)c1C(NOC[C@@H](CO)O)=O CPONMWDKPHGWME-GFCCVEGCSA-N 0.000 description 1
- UPHYKCROASETOT-UHFFFAOYSA-N OC(c1ccncc1Nc(ccc(I)c1)c1Cl)=O Chemical compound OC(c1ccncc1Nc(ccc(I)c1)c1Cl)=O UPHYKCROASETOT-UHFFFAOYSA-N 0.000 description 1
- RKLLGCYJVHTWGA-SNVBAGLBSA-N OC[C@H](CONC(c1ccncc1Nc(ccc(I)c1)c1F)=O)O Chemical compound OC[C@H](CONC(c1ccncc1Nc(ccc(I)c1)c1F)=O)O RKLLGCYJVHTWGA-SNVBAGLBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/28—Nitrogen atoms
- C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the invention relates to a series of substitued 3-arylamino pyridine derivatives that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
- the Ras/Raf/MEK/ERK pathway is a central signal transduction pathway, which transmits signals from multiple cell surface receptors to transcription factors in the nucleus which regulate gene expression.
- This pathway is frequently referred to as the MAP kinase pathway as MAPK stands for mitogen-activated protein kinase indicating that this pathway can be stimulated by mitogens, cytokines and growth factors (Steelman et al., Leukemia 2004, 18, 189-218).
- this pathway can transmit signals, which result in the prevention or induction of apoptosis or cell cycle progression.
- the Ras/Raf/MEK/ERK pathway has been shown to play important roles in cell proliferation and the prevention of apoptosis.
- Ras Aberrant activation of this pathway is commonly observed in malignantly transformed cells. Amplification of ras proto-oncogenes and activating mutations that lead to the expression of constitutively active Ras proteins are observed in approximately 30% of all human cancers (Stirewalt et al., Blood 2001, 97, 3589-95). Mutated, oncogenic forms of Ras are found in 50% of colon and >90% pancreatic cancers as well as many other types of cancers (Kohl et al., Science 1993, 260, 1834-1837). The effects of Ras on proliferation and tumorigenesis have been documented in immortal cell lines (McCubrey et al., lnt J Oncol 1995, 7, 295-310).
- bRaf mutations have been identified in more than 60%. of malignant melanoma (Davies, H et al., Nature 2002, 417, 949-954). Given the high level of mutations that have been detected at Ras, this pathway has always been considered a key target for therapeutic intervention (Chang et al., Leukemia 20O3, 77,1263-93).
- the Ras/Raf/MEK/ERK signaling pathway can exert proliferative or antiproliferative effects through downstream transcription factor targets including NF-KB, CREB, Ets-1, AP-1 and c-Myc.
- ERKs can directly phosphorylate Ets-1 , AP-1 and c-Myc, which lead to their activation.
- ERKs can phosphorylate and activate a downstream kinase target RSK, which then phosphorylates and activates transcription factors, such as CREB.
- These transcription factors induce the expression of genes important for cell cycle progression, for example, Cdks, cyclins, growth factors, and apoptosis prevention, for example, antiapoptotic Bcl-2 and cytokines.
- treatment of cells with growth factors leads to the activation of ERKs which results in proliferation and, in some cases, differentiation (Lewis et al., Adv. Cancer Res, 1998, 74, 49-139).
- MEK proteins are the primary downstream targets of Raf.
- the MEK family of genes consists of five genes: MEK1 , MEK2, MEK3, MEK4 and MEK5. This family of dual- specificity kinases has both serine/threonine and tyrosine kinase activity.
- the structure of MEK consists of an amino-terminal negative regulatory domain and a carboxy-terminal MAP kinase-binding domain, which is necessary for binding and activation of ERKs. Deletion of the regulatory MEK1 domain results in constitutive MEK1 and ERK activation (Steelman et al., Leukemia 2004, 18, 189-218).
- MEK1 is a 393-amino-acid protein with a molecular weight of 44 kDa (Crews et al., Science 1992, 258, 478-80). MEK1 is modestly expressed in embryonic development and is elevated in adult tissue with the highest levels detected in brain tissue. MEK1 requires phosphorylation of S218 and S222 for activation, and substitution of these residues with D or glutamic acid (E) led to an increase in activity and foci formation in NIH3T3 cells (Huang et al., MoI Biol Cell, 1995, 6, 237-45).
- MEK1 constitutive activity of MEK1 in primary cell culture promotes senescence and induces p53 and p16 INK4a , and the opposite was observed in immortalized cells or cells lacking either p53 or p 16 lNK4a (Lin et al., Genes Dev, 1998 , 12, 3008-3019).
- Constitutive activity of MEK1 inhibits NF- KB transcription by negatively regulating p38 MAPK activity (Carter et al., J Biol C hem 2000, 275, 27858-64).
- the main physiological substrates of MEK are the members of the ERK (extracellular signal-regulated kinase) or MAPK (mitogen activated protein kinase) family of genes. Aberrant expression of MEK1 has been detected in many different types of cancer, and mutated forms of MEK1 will transform fibroblast, hematopoietic and other cell types.
- MEK1 Constitutive activation of MEK1 results in cellular transformation. It therefore represents a likely target for pharmacological intervention in proliferative and inflammatory diseases (Lee et al., Nature 1994, 372, 739-746; Dudley et al., Proc. Natl. Acad. ScL U.S.A. 1995, 92, 7686-7689).
- MEK inhibitors have been developed that show potential therapeutic benefit in several studies. For example, small molecule MEK inhibitors have been shown to inhibit human tumor growth in nude mouse xenografts (Yeh, T. et al, Proceedings of the American Association of Cancer Research 2004, 45, Abs 3889 and Lee, P. et al., Proceedings of the American Association of Cancer Research 2004, 45, Abs 3890). MEK inhibitors also entered clinical trials, i.e. ARRY142886 (Wallace, E.
- PD-184352 was lacking efficacy in clinical phase Il trials. Tumors were much less responsive, as no partial responses and only a few patients with stable disease were observed. As a result, the clinical trials of this molecule were suspended (Mclnnes C IDDB MEETING REPORT 2003). PD-184352 was limited by poor solubility, high metabolic clearance and low bioavailability. This exemplifies the need for novel MEK inhibitors with superior pharmacological properties.
- the object of the present invention to provide novel MEK inhibitors useful in the treatment of hyperproliferative diseases related to the hyperactivity of MEK as well as diseases modulated by the MEK cascade, such as cancer and inflammation, in mammals with superior pharmacological properties both with respect to their activities as well as their solubility, metabolic clearance and bioavailability characteristics.
- this invention provides novel, substitued 3-arylamino pyridine derivatives and pharmaceutically acceptable salts, solvates or prodrugs thereof, that are MEK inhibitors and useful in the treatment of the above mentioned diseases.
- R 1 , R 2 , Rg, Rio, Rn Ri 2 , Rn and R 14 are independently selected from hydrogen, halogen, cyano, nitro, azido, -OR 3 , -C(O)R 31 -C(O)OR 3 , -NR 4 C(O)OR 6 , -OC(O)R 3 , - NR 4 S(O) 1 R 6 , -S(O)jNR 3 R 4 , -S(O) 1 NR 4 C(O)R 3 , -C(O)NR 4 S(O)jR 6 , S(O) 1 R 6 ,- NR 4 C(O)R 3 , -C(O)NR 3 R 41 -NR 5 C(O)NR 3 R 4 , -NR 5 C(NCN)NR 3 R 41 -NR 3 R 4 and C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3
- R 3 is selected from hydrogen, trifluoromethyl, C 1 -Ci 0 alkyl, C 2 -i 0 alkenyl, C 2 -C 10 alkynyl, C 3 -Ci 0 cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is substituted or unsubstituted;
- R 4 is selected from hydrogen or C 1 -C 6 alkyl whereby alkyl may be substituted or unsubstituted; or
- R 3 and R 4 can be taken together with the atom to which they are attached to form a 4 to 10 membered heteroaryl or heterocyclic ring, each of which is substituted or unsubstituted;
- R 5 is selected from hydrogen or C 1 -C 6 alkyl whereby alkyl may be substituted or unsubstituted; or
- R 4 and R 5 can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is substituted or unsubstituted;
- R 6 is selected from trifluoromethyl; and C 1 -C 10 alkyl, C 3 -C 10 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl substituted or unsubstituted;
- W is selected from heteroaryl containing 1-4 heteroatoms or heterocyclyl containing 1-4 heteroatoms each of which is unsubstituted or substituted by 1 to 5 substituents ZR 15 ; or W is -C(O)ORi 5 , -C(O)NR 4 Ri 5 , -C(O)NR 4 ORi 5 , -C(O)(C 3 -Ci 0 cycloalkyl), - C(O)(C 2 -Ci 0 alkyl), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocyclyl), S(O)jNR 4 Ri 5 , S(O)jNR 4 ORi 5 , -S(O)jNR 4 C(O)R 15 , -C(O)NR 4 S(O)jR 6 , -C(O)NR 4 NR 4 R -I 5 , - C(O)C(O)R
- Z is a bond, NR 16 , O, NRi 6 SO 2 or S j
- Ri 5 is independently selected from hydrogen, trifluoromethyl, C1-C10 alkyl, C 2 -Ci 0 alkenyl, C 2 -C 1 0 alkynyl, C3-C 1 0 cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is substituted or unsubstituted;
- R16 is selected from hydrogen or C1-C10 alkyl, or Ri 5 and R 16 form together a 4 to 10 membered cyclic ring with 1 or 2 N atoms and optionally an O atom, said ring being substituted or unsubstituted;
- Ri, R2, Rs, R10, R11 R12, Ri3 and Ri 4 are independently selected from hydrogen, halogen, cyano, nitro, azido, -OR 3 , -NR 4 C(O)OR 6 , -OC(O)R 3 , -NR 4 S(O)jR 6 , -S(O) j NR 3 R 4 , - S(O)jNR 4 C(O)R 3 , -C(O)NR 4 S(O)jR 6 , S(O)jR 6 ,-NR 4 C(O)R 3 , -C(O)NR 3 R 4 ,- NR 5 C(O)NR 3 R 4 , -NR 5 C(NCN)NR 3 R 41 -NR 3 R 4 and d-Cio alkyl, C 2 -C 10 alkenyl, C 2 - C 10 alkynyl, C 3 -Ci 0 cycloalkyl, C 3 -Ci 0 cycl
- R 3 is selected from hydrogen, trifluoromethyl, C 1 -C 10 alkyl, C 2 -i 0 alkenyl, C 2 -Ci 0 alkynyl, C 3 -C 1 0 cycloalkyl, C 3 -Ci 0 cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl and heterocyclyl is substituted or unsubstituted; or aryl which is unsubstituted or substituted with 1 to 5 groups independently selected from oxo, halogen, nitro, CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 , OCH 2 F, azido, NR 1 SO 2 R"", SO 2 NR", C(O)R', C(O)OR',
- R 4 is selected from hydrogen or C r C 6 alkyl whereby alkyl may be substituted or unsubstituted; or
- R 3 and R 4 can be taken together with the atom to which they are attached to form a 4 to 10 membered heteroaryl or heterocyclic ring, each of which is substituted or unsubstituted;
- R 5 is selected from hydrogen or C 1 -C 6 alkyl whereby alkyl may be substituted or unsubstituted; or
- R 4 and R 5 can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is substituted or unsubstituted;
- R 6 is selected from trifluoromethyl; and C 1 -Ci 0 alkyl, C 3 -Ci 0 cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl substituted or unsubstituted;
- R', R" and R"' are independently selected from hydrogen, CrC 4 alkyl, C 2 -C 4 alkenyl, aryl and arylalkyl;
- R" is selected from Ci-C 4 alkyl, C 1 -C 4 alkenyl, aryl and arylalkyl;
- W is selected from heteroaryl containing 1-4 heteroatoms or heterocyclyl containing 1-4 heteroatoms each of which is unsubstituted or substituted by 1 to 5 substituents ZR 15 ; or W is -C(O)OR 15 , -C(O)NR 4 R 15 , -C(O)NR 4 OR 15 , -C(O)(C 3 -C 10 c/cloalkyl), - C(0)(heterocyclyl), S(O)jNR 4 R 15 , S(O)jNR 4 OR 15 , -S(O)jNR 4 C(O)Ri 5 , - C(O)NR 4 S(O)JR 6 , -C(O)NR 4 NR 4 R 151 -C(O)C(O)R 15 , -C(O)CR 1 R 11 C(O)R 15 , -NR 1 R", - NR 1 C(O)R 1 , -NR 1 S(O)JR 1
- Z is a bond, NR 16 , O, NRi 6 SO 2 or S.
- R15 is independently selected from hydrogen, trifluoromethyl, Ci-Ci 0 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -Ci 0 cycloalkyl, C 3 -Ci 0 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is substituted or unsubstituted;
- R16 is selected from hydrogen or C 1 -Ci 0 alkyl, or R 15 and Ri 6 form together a 4 to 10 membered cyclic ring with 1 or 2 N atoms and optionally an O atom, said ring being substituted or unsubstituted;
- the compounds as defined by Formula (II) do not include the following compounds: 3-(4-Methoxy-phenylamino)-isonicotinic acid, that has been described as an intermediate in the synthesis of benzonaphthyridine derivatives as anti-malarial agents,
- the variants have the following meanings:
- Ri is as defined above, preferably hydrogen, halo, d-C 4 alkyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, cyano, nitro, OR 3 or NR 3 R 4 ; more preferably hydrogen, halo or C 1 - C 4 alkyl, still more preferably hydrogen or halo, most preferably hydrogen or F.
- Ri is hydrogen.
- R 2 is as defined above, preferably hydrogen, halo, Ci-C 4 alkyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, cyano, nitro, OR 3 or NR 3 R 4 ; more preferably hydrogen, halo Or C 1 - C 2 alkyl, still more preferably halo or methyl, most preferably Cl, F or methyl.
- R 2 is methyl.
- methyl is preferably further substituted by 1, 2 or 3 fluorines, preferably 3 fluorines. Most preferably, R 2 is F.
- R 9 is as defined above, preferably hydrogen, halo, C 1 -C 4 alkyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, cyano, nitro, OR 3 or NR 3 R 4 ; more preferably hydrogen, halo or C 1 - C 4 alkyl, still more preferably hydrogen, methyl or halo, most preferably hydrogen, methyl, Cl or F. In one embodiment, R 9 is hydrogen.
- R 10 is as defined above, preferably hydrogen, halo, C1-C10 alkyl, C 3 -Ci 0 cycloalkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, cyano, nitro, azido; NR 4 SO 2 R 6 ; SO 2 NR 3 R 4 ; SO 2 R 5 ; C(O)NR 3 R 4 ; C(O)OR 3 ; -S(O) J -NR 4 C(O)R 3 , -C(O)NR 4 S(O)jR 6 , OR 3 or NR 3 R 4 , more preferably hydrogen, halo, nitro, C 1 -C 4 alkyl, 0-C 1 -C 4 alkyl, SO 2 NR 3 R 4 or C(O)NR 3 R 4 , still more preferably hydrogen F, Cl 1 Br, nitro, methyl, O-methyl, SO 2 NR 3 R 4 Or C(O)NR 3 R 4 , most
- Ri 0 is hydrogen.
- R 10 is methyl.
- methyl is preferably further substituted by 1 , 2 or 3 fluorines, preferably 3 fluorines.
- R- I0 , R 3 and R 4 are independently C 1 -C 6 alkyl, more preferably C 1 -C 4 alkyl, optionally substituted by 1 or 2 alkyl amino, dialkyl amino, amino, O-alkyl, hydroxy, or R 3 and R 4 form together a cyclic ring with 1 or 2 N atoms and optionally an O atom, said ring being optionally substituted by 1 or 2 alkyl amino, amino, hydroxy or O-alkyl.
- R 11 is as defined above, preferably hydrogen, halo, C 1 -C 4 alkyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, cyano, nitro, OR 3 or NR 3 R 4 ; more preferably hydrogen, halo or Ci- C 4 alkyl or 0-C 1 -C 4 alkyl, still more preferably hydrogen, methyl, O-methyl or halo, most preferably hydrogen, methyl, Cl 1 Br or F.
- Rn is hydrogen.
- Rn is methyl.
- methyl is preferably further substituted by 1, 2 or 3 fluorines, preferably 3 fluorines.
- R 12 is as defined above, preferably hydrogen, halo, C 1 -C 10 alkyl, C 3 -C 10 cycloalkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, cyano, nitro, azido; NR 4 SO 2 R 6 ; SO 2 NR 3 R 4 ; SO 2 R 6 ; C(O)NR 3 R 4 ; C(O)OR 3 ; OR 3 , NR 3 R 4 or -S(C 1 -C 2 alkyl) substituted with 1 to 5 F 1 more preferably hydrogen, halo, nitro, C1-C4 alkyl, 0-C 1 -C 4 alkyl, SCF 3 , SCHF 2 , SCH 2 F, SO 2 NR 3 R 4 or C(O)NR 3 R 4 , still more preferably hydrogen, F, Cl, Br, nitro, methyl, O-methyl, SCF 3 , SCHF 2 , SCH 2 F, SO 2
- Ri 2 is hydrogen.
- R 12 is methyl, SCF 3 , SCHF 2 , SCH 2 F or O-methyl, wherein methyl or O- methyl is preferably unsubstituted or further substituted by 1 , 2 or 3 fluorines, preferably 2 or 3 fluorines.
- R 12 , R 3 and R 4 are independently C 1 -C 6 alkyl, more preferably CrC 4 alkyl, optionally substituted by 1 or 2 alkyl amino, dialkyl amino, amino, O-alkyl, hydroxy, or R 3 and R 4 form together a cyclic ring with 1 or 2 N atoms and optionally an O atom, said ring being optionally substituted by ⁇ or 2 alkyl amino, amino, hydroxy or O-alkyl.
- Ri 2 is Br or I.
- R 13 is as defined above, preferably hydrogen, halo, C r C 4 alkyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl or C 2 -C 4 alkynyl, more preferably hydrogen, F, Cl or methyl, most preferably hydrogen or F. in one embodiment, Ri 3 is hydrogen.
- R 14 is as defined above, preferably hydrogen, halo, Ci-C 4 alkyl, C 3 -C 4 cycloalkyl, C 2 -C 4 alkenyl Or C 2 -C 4 alkynyl, more preferably hydrogen, F, Cl or methyl, most preferably hydrogen or F.
- Ri 4 is hydrogen.
- each of R 1 , R 2 and R 9 to Ri 4 may be substituted.
- they can be substituted with 1 to 5, preferably 1 to 3, more preferably 1 or 2 groups independently selected from oxo, halogen, cyano, nitro, CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 , OCH 2 F, SCF 3 , SCHF 2 , SCH 2 F, azido, NR 4 SO 2 R 6 , SO 2 NR 3 R 4 , C(O)R 3 , C(O)OR 3 , OC(O)R 3 , NR 4 C(O)OR 6 , NR 4 C(O)R 3 , C(O)NR 3 R 4 , NR 3 R 4 , NR 5 C(O)NR 3 R 4 , NR 5 C(NCN)NR 3 R 4 , OR 3 , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heteroarylalkyl, hetero
- R 3 is as defined above, preferably hydrogen, trifluoromethyl, Ci-C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkylalkyl, more preferably hydrogen or C 1 -C 4 alkyl most preferably hydrogen, methyl or ethyl.
- R 4 is as defined above, preferably hydrogen or C r C 4 alkyl, more preferably hydrogen, methyl or ethyl.
- R 3 and R 4 can be taken together with the atom to which they are attached to form a 4 to 7, preferably 5 or 6, membered heteroaryl or heterocyclic ring.
- R 5 is as defined above, preferably hydrogen or d-C 4 alkyl, more preferably hydrogen, methyl or ethyl.
- R 4 and R 5 can be taken together with the atom to which they are attached to form a 4 to 7, preferably 5 or 6, membered carbocyclic, heteroaryl or heterocyclic ring.
- R 6 is as defined above, preferably trifluoromethyl, CrC 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkylalkyl, more preferably C1-C4 alkyl, most preferably methyl or ethyl.
- each of R 3 , R 4 , R5, Rs or the rings formed by R 3 and R 4 and R 4 and R 5 may be substituted.
- they can be substituted with 1 to 5, preferably 1 to 3, more preferably 1 or 2 groups independently selected from oxo, halogen, cya ⁇ o, nitro, CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 , OCH 2 F, azido, NR 1 SO 2 R"", SO 2 NR", SO 2 NR", SO 2 NR", SO 2 NR", C(O)R', C(O)OR', OC(O)R', NR 1 C(O)OR"", NR 1 C(O)R", C(O)NR 1 R", SR 11 ", S(O)R"", SO 2 R', NR 1 R", NR 1 C(O)NR 11 R 1 ", NR'C(NCN)NR"R"', OR', aryl, heteroaryl, arylal
- R' is selected from hydrogen, CrC 4 alkyl, C 2 -C 4 alkenyl, aryl and arylalkyl, preferably hydrogen or C 1 -C 4 alkyl, more preferably hydrogen or methyl.
- R" is selected from hydrogen, C 1 -C4 alkyl, C 2 -C 4 alkenyl, aryl and arylalkyl, preferably hydrogen or d-C 4 alkyl, more preferably hydrogen or methyl.
- R'" is selected from hydrogen, CrC 4 alkyl, C 2 -C 4 alkenyl, aryl and arylalkyl, preferably hydrogen or d-C 4 alkyl, more preferably hydrogen or methyl.
- R" is selected from C 1 -C4 alkyl, C 1 -C4 alkenyl, aryl and arylalkyl, preferably Ci-C 4 alkyl, more preferably methyl.
- any two of R 1 , R", R 1 " or R"" can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano; nitro, CF 3 , CHF 2 , CH 2 F, OCF 3 , OCHF 2 , OCH 2 F, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, preferably halogen, cyano; nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy and azido.
- W is as defined above, preferably heteroaryl containing 1 , 2 or 3 heteroatoms, or heterocyclyl containing 1, 2, or 3 heteroatoms, more preferably heteroaryl, each of which is unsubstituted or substituted by 1 to 5, preferably 1 to 3, more preferably 1 , substituents ZR 15 , or W is -C(O)OR 15 , -C(O)NR 4 R 15 , -C(O)NR 4 OR 15 , -C(O)(C 3 -C 10 cycloalkyl), - C(O)(C 2 -Ci 0 alkyl), -S(O)jNR 4 C(O)Ri 5 , -C(O)NR 4 S(O)jR 6 , S(O)jNR 4 R 15 or S(O)jNR 4 ORi 5 , more preferably W is heteroaryl containing 1 , 2, or 3, specifically 2 or 3 N atoms, C(O)NR 4 OR 15 Or S(O) 2
- W is heteroaryl, it is preferably
- Z and R 15 are as defined above, preferably Z is a bond, NRi 6 , NRi 6 SO 2 or O, more preferably NRi 6 , wherein R 16 is as defined above, preferably hydrogen or Ci-C 4 alkyl, more preferably hydrogen.
- Ri 5 is preferably selected from hydrogen, Ci-C 4 alkyl, C 1 -C4 alkenyl, C 4 -C 8 cycloalkylalkyl, each may contain 1 N atom optionally an O atom, where alkyl, alkenyl or cycloalkylalkyl may be further substituted by 1 or 2 of OH, 0-Ci-C 4 alkyl or NR'R", where R' and R" are independently hydrogen Or C 1 -C 4 alkyl where R'and R" form a 3 to 7 membered ring with 1 or 2 N atoms and optionally an O atom.
- R 16 and R 15 may form together a 4 to 10 membered cyclic ring with 1 or 2 N atoms and optionally an O atom, said ring being optionally substituted by 1 or 2 alkyl amino, amino, hydroxy or O-alkyl. More preferably R 15 is Ci-C 4 alkyl or C r C 4 alkenyl optionally substituted with 1 substitutent OH, O-Me, NH 2 , N(methyl) 2 or N(ethyl) 2 .
- Y is O or NR', preferably O.
- W is preferably -C(O)ORi 5 , -C(O)NR 4 Ri 5 , -C(O)NR 4 OR 15 , S(O)jNR 4 Ri 5 or S(O)jNR 4 OR 15 , more preferably -C(O)NR 4 OR 15 or S(O) 2 NR 4 ORi 5 .
- R 15 is preferably as defined below.
- R 2 , R 12 , R 1 3 and R 14 are independently selected from hydrogen, halogen, cyano, nitro, azido, -NR 4 C(O)OR 6 , - OC(O)R 3 , -NR 4 S(O)jR 6 , -S(O)jNR 3 R 4 , -S(O)jN R 4 C(O) R 3 , -C(O)N R 4 S(O)jR 6> S(O)jR 6 ,- NR 4 C(O)R 3 , -NR 5 C(O)NR 3 R 4 , -NR 5 C(NCN)NR 3 R 4 and C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 - C 10 alkynyl, C 3 -C 10 cycloalkyl, C 3 -Ci 0 cycloalkylalkyl, -
- R 1 , F? 2 , Ri 2 , Ri3 and Ri 4 are as described above, and R 33 is preferably selected from hydrogen, CF 3 , CHF 2 , CH 2 F, C 2 -C 4 alkyl and C 2 -io alkenyl, and R 44 is selected from hydrogen, CF 3 , CHF 2 , CH 2 F and C 2 -C 4 alkyl.
- Z is as defined above, preferably a bond, NRi 6 , NRi 6 SO 2 or O, more preferably NRi 6 .
- Ri 5 is as defined above, preferably hydrogen, d-C 4 alkyl, CrC 4 alkenyl, C 4 -C 6 cycloalkylalkyl, more preferably C r C 4 alkyl or d-C 4 alkenyl, yet more preferably Ci-C 4 alkyl.
- Alkyl or alkenyl may be further substituted with 1 to 5, preferably 1 , 2 or 3, more preferably 1 or 2, substituents selected from OR 3 or NR'R" wherein R 3 is selected from hydrogen, CrC 4 alkyl or CrC 4 alkenyl, C 4 -C 6 cycloalkylalkyl, more preferably hydrogen, methyl or ethyl, and where R J and R" are independently hydrogen or CrC 4 alkyl, more preferably hydrogen, methyl or ethyl, still more preferably both R' and R" are methyl. Yet more preferably, R 15 may be substituted by 1 or 2 of OH, 0-CrC 4 alkyl or NR'R".
- Ri 5 is CrC 4 alkyl or CrC 4 alkenyl optionally substituted with 1 substitutent OH, O-Me, NH 2 , N(methyl) 2 or N(ethyl) 2 .
- R 16 is as defined above, preferably hydrogen or C 1 -C 4 alkyl, more preferably hydrogen.
- R 16 and R 15 may form together a 4 to 10, preferably 5 to S, membered cyclic ring with 1 or 2 N atoms and optionally an O atom, said ring being optionally substituted by 1 or 2 alkyl amino, amino, hydroxy or O-alkyl.
- X is as defined above. In one embodiment X is N, in another embodiment X is N- ⁇ O. m is as defined above, preferably 0,1,2 or 3, more preferably 0,1 or 2, most preferably 1. j is as defined above, preferably 2.
- any of the preferred definitions for each variant can be combined with the preferred definition of the other variants.
- Aryl is an aromatic mono- or polycyclic moiety with preferably 6 to 20 carbon atoms which is preferably selected from phenyl, biphenyl, naphthyl, tetrahydronaphthyl, fluorenyl, indenyl or phenanthrenyl, more preferably phenyl or naphthyl.
- Heteroaryl is an aromatic moiety having 6 to 20 carbon atoms with at least one ring containing a heteroatom selected from O, N and/or S, or heteroaryl is an aromatic ring containing at least one heteroatom selected from O, N and/or S and 1 to 6 carbon atoms.
- heteroaryl contains 1 to 4, more preferably 1 , 2 or 3 heteroatoms selected from O and/or N and is preferably selected from pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl, furazanyl,
- heteroaryl examples include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, isoxazolyl, oxazolyl, isothiazolyl, oxadiazolyl, triazolyl.
- Heteroaryl groups are optionally mono-, di-, or trisubstituted with, e.g., halogen, lower alkyl, lower alkoxy, haloalkyl, aryl, heteroaryl, and hydroxy.
- Heterocyclyl is a saturated or unsaturated ring containing at least one heteroatom selected from O, N and/or S and 1 to 6 carbon atoms.
- heterocyclyl contains 1 to 4, more preferably 1 , 2 or 3 heteroatoms selected from O and/or N and is preferably selected from pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,
- Carbocyclyl is a monocyclic or polycyclic ring system of 3 to 20 carbon atoms which may be saturated, unsaturated or aromatic.
- Alkyl is a saturated hydrocarbon moiety, namely straight chain or branched alkyl having 1 to 10, preferably 1 to 8 carbon atoms, more preferably 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl or heptyl.
- Cycloalkyl is an alkyl ring having 3 to 10, preferably 3 to 8 carbon atoms, more preferably 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
- Alkenyl is an unsaturated hydrocarbon moiety with one or more double bonds, preferably one double bond, namely straight chain or branched alkenyl having 1 to 10, preferably 2 to 8 carbon atoms, more preferably 2 to 4 atoms, such as vinyl, allyl, methallyl, buten-2- yl, buten-3-yl, penten-2-yl, penten-3-yl, penten-4-yl, 3-methyl-but-3-enyl, 2-methyl-but-3- enyl, 1-methyl-but-3-enyl, hexenyl or heptenyl.
- Alkynyl is an unsaturated hydrocarbon moiety with one or more triple bonds, preferably one triple bond, namely straight chain or branched alkynyl having 1 to 10, preferably 2 to 8 carbon atoms, more preferably 2 to 4 atoms, such as ethynyl, propynyl, butyn-2-yl, butyn-3-yl, pentyn-2-yl, pentyn-3-yl, pentyn-4-yl, 2-methyl-but-3-ynyl, 1 -methyl-but-3-ynyl, hexynyl or heptynyl.
- Halo or halogen is a halogen atom preferably selected from F, Cl, Br and I 1 preferably F, Cl and Br.
- cycloalkylalkyl, arylalkyl, heretoarylalkyl and heterocyclylalkyl it is contemplated that cycloalkyl, aryl, heretoaryl and heterocyclyl are bonded via an alkylene moiety.
- This alkylene moiety may be a straight chain or branched chain group.
- Said alkylene moiety preferably has 1 to 6 carbon atoms.
- Examples thereof include methylene, ethylene, n-propylene, n-butylene, n-pentylene, n-hexylene, iso-propylene, sec.-butylene, tert.-butylene, 1,1 -dimethyl propylene, 1,2-dimethyl propylene, 2,2- dimethyl propylene, 1 ,1-dimethyl butylene, 1 ,2-dimethyl butylene, 1 ,3-dimethyl butylene, 2,2-dimethyl butylene, 2,3-dimethyl butylene, 3,3-dimethyl butylene, 1 -ethyl butylene, 2- ethyl butylene, 3-ethyl butylene, 1 -n-propyl propylene, 2-n-propyl propylene, 1-iso-propyl propylene, 2-iso-propyl propylene, 1 -methyl pentylene, 2-methyl pentylene, 3-methyl pentylene and 4-methyl
- Carboxy refers to the group -C(O)OR, where R includes hydrogen or "d-Ce-alkyl”.
- Acyl refers to the group -C(O)R where R includes “Ci-C 6 -alkyl", “aryl” , “heteroaryl”, “C 3 - Cs-cycloalkyl”, “C 3 -C 8 -heterocycloalkyl", “Ci-C 6 -alkyl aryl” or “Ci-C 6 -alk/l heteroaryl”.
- Acyloxy refers to the group -OC(O)R where R includes "d-Ce-alkyl", “aryl”, “hetero- aryl”, “C r C 6 -alkyl aryl” or “C r C 6 -alkyl heteroaryl”.
- Aryl acyl refers to aryl groups having an acyl substituent, including 2-acetylphenyl and the like.
- Heteroaryl acyl refers to heteroaryl groups having an acyl substituent, including 2- acetylpyridyl and the like.
- Alkoxy refers to the group -O-R where R includes "C r C 6 -alkyl”, “C 2 -C 6 -alkenyl”, “C 2 -C 6 - alkynyl", “C 3 -C 8 -cycloalkyl", “Heterocycloalkyl”,”heterocycloalkyl", “aryl”, “heteroaryl”, “C 1 -Ce- alkyl aryl” or “Ci-C 6 -alkyl heteroaryl", “C 2 -C 6 -alkenyl aryl”, “C 2 -C 6 -alkenyl heteroaryl", “C 2 -Ce- alkynyl aryl”, “C 2 -C 6 -alkynylheteroaryl", “C r C 6 -alkyl cycloalkyl", “C r C 6 -alkyl heterocycloalkyl”.
- Preferred alkoxy groups include by way of example
- Alkoxycarbonyl refers to the group -C(O)OR where R includes "Ci-C 6 -alkyl” or “aryl” or “heteroaryl” or "Ci-C 6 -alkyl aryl” or “C r C 6 -alkyl heteroaryl”.
- Alkoxycarbonylamino refers to the group -NR 1 C(O)OR where R includes "CrC 6 -alky I” or “aryl” or “heteroaryl” or “Ci-C 6 -alkyl aryl” or “C r C 6 -alkyl heteroaryl”a and R' includes .hydrogen or "Ci-Ce-alkyl
- Aminocarbonyl refers to the group -C(O)NRR 1 where each R, R 1 includ&s independently hydrogen or C r C 6 -alkyl or aryl or heteroaryl or "CrC 6 -alkyl aryl” or "C 1 -Cs- alkyl hetero-aryl”.
- Acylamino refers to the group -NR(CO)R' where each R, R' is independently hydrogen or "d-Cs-alkyl” or “aryl” or “heteroaryl” or "d-C 6 -alkyl aryl” or "Ci-C 6 -alkyl heteroaryl”.
- “Sulfonyloxy” refers to a group -OSO 2 -R wherein R is selected from H 1 "d-Ce-alkyl", “d-Ce-alkyl” substituted with halogens, e.g., an -OSO 2 -CF 3 group, "C 2 -C 6 -alkenyr', "C 2 - Ce-alkynyl", “Cs-drcycloalkyl", “heterocycloalkyl", “aryl”, “heteroaryl”, “d-C 6 -alkyl aryl” or “d-Ce-alkyl heteroaryl", "C 2 -C 6 -alkenyl aryl", “C 2 -C 6 -alkenyl heteroaryl", “C 2 -C 6 -alkynyl aryl”, “C 2 -C 6 -alkynylheteroaryl”, “d-C 6 -alkyl cycloalkyl
- “Sulfonyl” refers to group “-SO 2 -R" wherein R is selected from H, "aryl", “heteroaryl”, “C 1 -C 6 - alkyl", “CrC 6 -alkyl” substituted with halogens, e.g., an -SO 2 -CF 3 group, "C 2 -C 6 -alkenyl”, “C 2 - Ce-alkynyl”, “C 3 -C 8 -cycloalkyl”, “heterocycloalkyl", “aryl”, “heteroaryl”, “d-C 6 -alkyl aryl” or "C 1 - Ce-alkyl heteroaryl", “C 2 -C 6 -alkenyl aryl", “C 2 -C 6 -alkenyl heteroaryl", “C 2 -C 6 -alkynyl aryl”, “C 2 - C 6 -alkynylheteroaryl", "C
- “Sulfinyl” refers to a group “-S(O)-R” wherein R is selected from H, “d-Ce-alkyl", “C 1 -C 6 - alkyl” substituted with halogens, e.g., an -SO-CF 3 group, "C 2 -C 6 -alkenyr, "C 2 -C 6 -alkynyr' I "Ca-Ca-cycloalkyl", “Heterocycloalkyl”,”heterocycloalkyl", “aryl”, “heteroaryl", “C r C 6 -alkyl aryl” or "d-Ce-alkyl heteroaryl", “C 2 -C 6 -alkenyl aryl”, “C 2 -C 6 -alkenyl heteroaryl", “C 2 -C 6 -alkynyl aryl”, “C 2 -C 6 -alkynylheteroaryl", "C
- Sulfanyl refers to groups -S-R where R includes H, "d-C 6 -alkyl", “Ci-C 6 -alkyl” optionally substituted with halogens., e.g a -S-CF 3 group, "C 2 -C 6 -alkenyl”, “C 2 -C 6 -alkynyr, “C 3 -C 8 - cycloalkyl", “heterocycloalkyl", “aryl”, “heteroaryl”, “C r C 6 -alkyl aryl” or “C r C 6 -alkyl heteroaryl", "C 2 -C 6 -alkenyl aryl", “C 2 -C 6 -alkenyl heteroaryl", “C 2 -C 6 -alkynyl aryl", “C 2 -C 6 - alkynylheteroaryl”, “d-Ce-alkyl cycloalkyl", "
- “Sulfonylamino” refers to a group -NRSO 2 -R' where each R, R' includes independently hydrogen, "d-C 6 -alkyl", “C 2 -C 6 -alkenyl”, “C 2 -C 6 -alkynyl", “C 3 -C 8 -cycloalkyl", “heterocycloalkyl", “aryl”, “heteroaryl”, “d-C 6 -alkyl aryl” or “d-C 6 -alkyl heteroaryl", “C 2 -C 6 - alkenyl aryl", “C 2 -C 6 -alkenyl heteroaryl", “C 2 -C 6 -alkynyl aryl", “C 2 -C 6 -alkynylheteroaryl”, “d- C 6 -alkyl cycloalkyl", “C r C 6 -alkyl heterocycloalkyl”.
- Aminosuifonyl refers to a group -SO 2 -NRR' where each R, R' includes independently hydrogen, "C r C 6 -alkyl", “C 2 -C 6 -alkenyl”, “C 2 -C 6 -alkynyl", “C 3 -C 8 -cycloalkyl", “heterocycloalkyl", “aryl”, “heteroaryl”, “d-C 6 -alkyl aryl” or “d-C 6 -alkyl heteroaryl", "C 2 - Ce-alkenyl aryl", “C 2 -C 6 -alkenyl heteroaryl", “C 2 -C 6 -alkynyl aryl", “C 2 -C 6 - alkynylheteroaryl”, “C r C 6 -alkyl cycloalkyl”, “d-C 6 -alkyl heterocycloalkyl”.
- Amino refers to the group -NRR' where each R, R' is independently hydrogen, "CrC 6 - alkyl", “C 2 -C 6 -alkenyl”, “C 2 -C 6 -alkynyl”, “C 3 -C 8 -cycloalkyl”,
- Heterocycloalkyl "heterocycloalkyl”
- aryl “heteroaryl”
- C r C 6 -alkyl aryl or "Ci-C 6 -alkyl heteroaryl”
- C 2 -C 6 -alkenyl aryl "C 2 -C 6 -alkenyl heteroaryl
- C 2 -C e alkynyl aryl
- C 2 -C 6 - alkynylheteroaryl "Ci-C 6 -alkyl cycloalkyl"
- CrC 6 -alkyl heterocycloalkyl and where R and R', together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered hetero-cycloalkyl ring.
- substitution is meant to also comprise situations where neighboring substituents undergo ring closure, in particular when vicinal functional substituents are involved, thus forming e.g. lactams, lactons, cyclic anhydrides, but also acetals, thioacetals, aminals formed by ring closure for instance in an effort to obtain a protective group.
- the compounds of the present invention can be in the form of a prodrug compound.
- Prodrug compound means a derivative that is converted into a compound according to the present invention by a reaction with an enzyme, gastric acid or the like under a physiological condition in the living body, e.g. by oxidation, reduction, hydrolysis or the like, each of which is carried out enzymatically.
- prodrug examples include compounds, wherein the am ino group in a compound of the present invention is acylated, alkylated or phosphorylated to form, e.g., eicosanoylamino, alanylamino, pivaloyloxymethylamino or wherein the hydroxyl group is acylated, alkylated, phosphorylated or converted into the borate, e.g. acetyloxy, palmitoyloxy, pivaloyloxy, succinyloxy, fumaryloxy, alanyloxy or wherein the carboxyl group is esterified or amidated.
- These compounds can be produced from compounds of the present invention according to well-known methods.
- prodrug examples are compounds, wherein the carboxylate in a compound of the present invention is for example converted into an alkyl-, aryl-, choline-, amino, acyloxymethylester, linolenoyl-ester.
- Metabolites of compounds of the present invention are also within the scope of the present invention.
- isomers can be separated by methods well known in the art, e.g. by liquid chromatography. Same applies for enantiomers by using e.g. chiral stationary phases. Additionally, enantiomers may be isolated by converting them into diastereomers, i.e. coupling with an enantiomerically pure auxiliary compound, subsequent separation of the resulting diastereomers and cleavage of the auxiliary residue. Alternatively, any enantiomer of a compound of the present invention may be obtained from stereoselective synthesis using optically pure starting materials.
- the compounds of the present invention can be in the form of a pharmaceutically acceptable salt or a solvate.
- pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids, including inorganic bases or acids and organic bases or acids.
- the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts.
- the compounds of the of the present invention which contain acidic groups can be present on these groups and can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts.
- salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino adds.
- Compounds of the present invention which contain one or more basic groups, i.e. groups which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids.
- acids examples include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art.
- the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions).
- inner salts or betaines can be obtained by customary methods which are known to the person skilled in the art like, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts .
- the present invention also includes all salts of the compounds of the present invention which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
- the present invention provides pharmaceutical compositions comprising a compound of the present invention, or a prodrug compound thereof, or a pharmaceutically acceptable salt or solvate thereof as active ingredient together with a pharmaceutically acceptable carrier.
- “Pharmaceutical composition” means one or more active ingredients, and one or more inert ingredients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
- a pharmaceutical composition of the present invention may additionally comprise one or more other compounds as active ingredients like one or more additional compounds of the present invention, or a prodrug compound or other MEK inhibitors.
- said compounds and pharmaceutical composition are for the treatment of cancer such as brain, lung, squamous cell, bladder, gastic, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, oesohageal, testicular, gynecological or thyroid cancer.
- said pharmaceutical composition is for the treatment of a noncancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g. benign prostatic hypertrophy (BPH)).
- benign hyperplasia of the skin e.g., psoriasis
- restenosis e.g. benign prostatic hypertrophy (BPH)
- the invention also relates to the use of compounds according to formula (I) or formula (II) for the preparation of a medicament for the treatment of hyperproliferative diseases related to the hyperactivity of MEK as well as diseases modulated by the MEK cascade in mammals, or disorders mediated by aberrant proliferation, such as cancer.
- the invention also relates to a compound or pharmaceutical composition for the treatment of pancreatitis or kidney disease (including proliferative glomerulonephtitis and diabetes induced renal disease) or pain in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier.
- the invention also relates to a compound or pharmaceutical composition for the prevention of blastocyte implantation in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier.
- the invention also relates to a compound or pharmaceutical composition for treating a disease related to vasculogenesis or angiogenesis in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier.
- said compound or pharmaceutical composition is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, skin diseases such as psoriasis, excema, and scleredema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
- a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, skin diseases such as psoriasis, excema, and scleredema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangiom
- the invention also relates to of the use for treating a hyperproliferati ve disorder in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
- said use relates to the treatment of cancer such as brain, lung, squamous cell, bladder, gastic, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, oesohageal, testicular, gynecological or thyroid cancer.
- said use relates to the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g., benign prostatic hypertrophy (BPH)).
- a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g., benign prostatic hypertrophy (BPH)).
- the invention also relates to a use for the treatment of a hyperproliferative disorder in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, topoisomerase inhibitors, biological response modifiers, antihormones, angiogenesis inhibitors, and anti- androgens.
- an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, topoisomerase inhibitors, biological response modifiers, antihormones, angiogenesis inhibitors, and anti- androgens.
- the invention also relates to a use of treating pancreatitis or kidney disease or pain in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
- the invention also relates to a use of preventing blastocyte implantation in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
- the invention also relates to a use of treating diseases related to vasculogenesis or angiogenesis in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
- said method is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
- a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma,
- Patients that can be treated with compounds of the present invention, or pharmaceutically acceptable salts, prodrugs and hydrates of said compounds, according to the methods of this invention include, for example, patients that have been diagnosed as having psoriasis, restenosis, atherosclerosis, BPH, lung cancer, bone cancer, CMML, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, testicular, gynecologic tumors (e.g., uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system (e.g., cancer of the thyroid, parathyroid or adrenal glands
- This invention also relates to a compound or pharmaceutical composition for inhibiting abnormal cell growth in a mammal which comprises an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate or prodrug thereof, in combination with an amount of a chemotherapeutic, wherein the amounts of the compound, salt, solvate, or prodrug, and of the chemotherapeutic are together effective in inhibiting abnormal cell growth.
- chemotherapeutics are presently known in the art.
- the chemotherapeutic is selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens.
- This invention further relates to a method for inhibiting abnormal cell growth in a mammal or treating a hyperproliferative disorder which method comprises administering to the mammal an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate or prodrug thereof, in combination with radiation therapy, wherein the amounts of the compound, salt, solvate, or prodrug, is in combination with the radiation therapy effective in inhibiting abnormal cell growth or treating the hyperproliferative disorder in the mammal.
- Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapy described herein.
- the administration of the compound of the invention in this combination therapy can be determined as described herein.
- this invention further relates to a method for sensitizing abnormal cells in a mammal to treatment with radiation which comprises administering to the mammal an amount of a compound of the present invention or pharmaceutically acceptable salt or solvate or prodrug thereof, which amount is effective is sensitizing abnormal cells to treatment with radiation.
- the amount of the compound, salt, or solvate in this method can be determined according to the means for ascertaining effective amounts of such compounds described herein.
- the invention also relates to a method of and to a pharmaceutical composition of inhibiting abnormal cell growth in a mammal which comprises an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof, a prodrug thereof, or an isotopically-labeled derivative thereof, and an amount of one or more substances selected from anti-angiogenesis agents, signal transduction inhibitors, and antiproliferative agents.
- the compounds of the present invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
- the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
- any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
- oral liquid preparations such as, for example, suspensions, elixirs and solutions
- carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparation
- tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained.
- the active compounds can also be administered intranasally as, for example, liquid drops or spray.
- the tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin.
- a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
- tablets may be coated with shellac, sugar or both.
- a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
- Compounds of the present invention may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
- Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present invention.
- oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed.
- Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
- compounds of the present invention are administered orally.
- the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
- the compounds of the present invention are administered at a daily dosage of from about 0.1 milligram to about 100 milligram per kilogram of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form.
- the total daily dosage is from about 1.0 milligrams to about 1000 milligrams, preferably from about 1 milligram to about 50 milligrams. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 milligrams to about 350 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.
- LiHMDS Lithium hexamethyldisilazide
- the compounds of the present invention can be prepared according to the procedures of the following Schemes and Examples, using appropriate materials and are further exemplified by the following specific examples. Moreover, by utilizing the procedures described herein, in conjunction with ordinary skills in the art, additional compounds of the present invention claimed herein can be readily prepared.
- the compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention.
- the examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds.
- the instant compounds are generally isolated in the form of their pharmaceutically acceptable salts, such as those described above.
- the amine-free bases corresponding to the isolated salts can be generated by neutralization with a suitable base, such as aqueous sodium hydrogencarbonate, sodium carbonate, sodium hydroxide and potassium hydroxide, and extraction of the liberated amine-free base into an organic solvent, followed by evaporation.
- a suitable base such as aqueous sodium hydrogencarbonate, sodium carbonate, sodium hydroxide and potassium hydroxide
- the amine-free base, isolated in this manner can be further converted into another pharmaceutically acceptable salt by dissolution in an organic solvent, followed by addition of the appropriate acid and subsequent evaporation, precipitation or crystallization.
- Scheme 2 illustrates the synthesis of compounds in the present invention.
- the aniline 1 is reacted with 3-fluoro isonicotinic acid in an inert solvent, preferable THF, by addition af a base, preferably but not limited to LiHMDS.
- the 3-anilino isonicotinic acid 2 is coupled with an O-alkyl hydroxalamine using an appropriate coupling reagent including but not limited to PyBOP; EDC or DCC in a suitable organic solvents like for example DMF, THF or DCM to yield hydroxamate 3.
- Compound 3 is then converted into the corresponding pyridine N-oxide 4 by using oxidation reagents as for example MCPBA or peracetic acid in a suitable solvent like for example THF or DCM.
- Suitable anilines and isonicotinic acid derivatives are commercially available from Sigma- Aldrich Chemie GmbH, Kunststoff, Germany or from Acros Organics, Belgium or from Fisher Scientific GmbH, 58239 Schense, Germany or can be routinely prepared by procedures described in"March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 5th Edition; John Wiley & Sons.
- Scheme 3 illustrates the preparation of compounds of the present invention where W is heterocyclic.
- step 1 the 3-anilino isonicotinic acid derivative 5 is reacted with pentafluorophenyl trifluoroacetate and a base, for example pyridine, to give the active ester 6 which is further converted in step 2 to hydrazide 7 by reacting it with hydrazine or hydrazine hydrate in an inert solvent such as DCM, DMF or THF.
- Reaction of 7 with CDI or any suitable carbonate equivalent in a preferred solvent such as DMF or DCM for example then gives Oxadiazolone 8, which forms N-substiutued hydrazinecarboxamides 9 when treated with a substitued amine in ethanol.
- Cyclization is achived by adddition of triphenylphosphine and a base such as triethylamine or DIPEA in an inert solvent like CCI 4 for example to give compound 10.
- Analytical LC/MS was performed using Reprosil-Pur ODS3, 5 ⁇ M, 1 x 60 mm columns at a flow rate of 250 ⁇ l/min, sample loop 2.5 ⁇ l; retention times are given in minutes.
- Methods are: (I) runs on a LC10Advp-Pump (Shimadzu) with SPD- M1 OAvp UV ⁇ /is diode array detector and QP2010 MS-detector in ES l+ modus with UV- detection at 214, 254 and 275 nm with a gradient of 15-95% acetonitrile (B) in water (A) (0.1% formic acid), 5 min.
- Lithium 1,1,1 ,3,3,3-hexamethyldisilazan-2-ide (62 ml ,62.0 mmol) was added to a solution of 2- fluoro-4-iodoaniline (7.24g, 30.55 mmol) in THF at -78 0 C.
- the mixtuire was stirred for 90 min at -78 0 C, then another 1.2 equiv. of lithium 1 ,1 ,1, 3,3, 3-hexam ethyldisilazan-2-ide (3r1 ml ,31.0 mmol) was added, following by 3-fluoroisonicotinic acid 1-ox ⁇ de (4.0 g, 25.46 mmol).
- Lithium 1 ,1 ,1 , 3,3, 3-hexamethyldisilazan-2-ide (11.9 ml, 1.0C M, 1 1.82 mmol) was added to a solution of 2-fluoro-4-iodoaniline (1.4Og ,5.91 mmol) at -78 0 C. The pale green colored solution was stirred for 1 1/2h at -78 0 C. Then, lithium 1,1,1 ,3,3,3-hexamethyldisilazan-2-ide (5.45 ml, 1.00 M, 5.45 mmol) was added followed by 2-bromo-5-fluoroisonicotinic acid (LOOg ,4.55 mmol) in THF (5 ml).
- Lithium bis(trimethylsilyl)amide (2.8 ml, 1.0 M in THF, 2.76 mmol) was added to a suspension of 5-fluoro-2-phenylisonicotinic acid (500 mg , 2.30 mmol) in THF (10 ml) at -78 0 C. The dark colored suspension was stirred for 30 min.
- 2-fl uoro-4-iodoaniline (709.30mg, 2.99 mmol ,1.30eq) was dissolved in (15 ml) THF and cooled to -78 0 C.
- Example 7a N- ⁇ [(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy ⁇ -3-[(2-fluoro-4- ⁇ odophenyl)amino]isonicotinamide:
- Example 7b 3-[(2-chloro-4-iodophenyl)amino]-N- ⁇ [(4R)-2,2-dimethyl-1 ,3-dioxolan-4-y I] methoxy ⁇ isonicotinamide:
- 3-(2-Fluoro-4-iodo-phenylamino)-N-(2-morpholin-4-yl-ethyl)-isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.35 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.50 mmol of. 2- morpholin-4-yl-ethylamine LC/MS [1.74 min; 471 (M+1)].
- Example 1 5 3-(2-Fluoro-4-iodo-phenylamino)-N-(2-hydroxy-ethyl)-isonicotinamide:
- N-ethyl-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1, outlined above, starting with 0.34 mmol of 3-[(2-fluoro-4- iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.48 mmol of monoethylamine.
- LC/MS [5.96 min; 386 (M + 1)]
- N-benzyl-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1, outlined above, starting with 0.3 mmol 3-[(2-fluoro-4- iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.45 mmol of benzylamine.
- LC/MS [7.55 min; 448 (M + 1)]
- N' ⁇ S- ⁇ -fluoro- ⁇ iodophenyOaminoJisonicotinoylj-I H-indaziole-S-carbohydrazide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.32 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.47 mmol of I H-indazole-3-carboxylic acid hydrazide.
- LC/MS [ ⁇ .14 min; 517 (M + 1)]
- Example 34 tert-butyl(1 - ⁇ 3-[(2-fluoro-4-iodophenyl)amino]isonicotinoyl ⁇ -piperidin-4- yl)carbamate:
- tert-butyl(1- ⁇ 3-[(2-fluoro-4-iodophenyl)amino]isonicotinoyl ⁇ piperidin-4-yl)carbamate was synthesized according to the procedure for General Method 1 , outlined above, starting with 2.4 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 4.0 mmol of piperidin-4-yl-carbamic acid tert-butyl ester.
- LC/MS [9.47 min; 541 (M + 1)]
- N-azepan-1-yl-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.45 mmol of 3-[(2-fluoro- 4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 6.2 mmol of azepan-1-ylamine.
- LC/MS [8.99 min; 455 (M + 1)]
- Example 44 4-[(4-aminopiperidin-1-yl)carbonyl]-N-(2-fluoro-4-iodophenyl)pyridin-3- amine hydrochloride:
- Example 45 tert-butyl 2- ⁇ 3-[(2-fluoro-4-iodophenyl)amino]-isonicotinoyl ⁇ hydrazine- carboxylate:
- tert-butyl 2- ⁇ 3-[(2-fluoro-4-iodophenyl)amino]isonicotinoyl ⁇ hydrazine-carboxylate was synthesized according to the procedure for General Method 1, outlined above, starting with 3 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 5 mmol of hydrazinecarboxylic acid tert-butylester.
- N-cyclopropyl-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1, outlined above, starting with 0.2 mmol of 3-[(2-fluoro-4- iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.23 mmol of cycle* propylamine.
- LC/MS [8.78 min; 398 (M + 1)]
- Example 48 3-[(2-fluoro-4-iodophenyl)amino]-N-[(2R)-2-hydroxypropyl]- isonicotinamide:
- Example 50 a- ⁇ -fluoro ⁇ -iodophenylJaminol-N'- ⁇ -ttrifluoromethylJpyrimidin ⁇ - yl]isonicotinohydrazide:
- 5-fluoro-2-(4-methoxyphenyl)isonicotinic acid was synthesized from 765 mg (3.76 mmol) of 5-fluoro-2-(4-methoxyphenyl)pyridine, butyllithium (1.8 ml, 2.50 M in THF ,4.52 mmol) and dry ice. Yield: 450 mg, 48%.
- N-(cyclopropylmethyl)-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.2 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.23 mmol of cydopropylmethylamine.
- LC/MS [9.79 min; 412 (M + 1)]
- Example 56 N'-tT-chloroquinolin- ⁇ ylJ-S- ⁇ -fluoro- ⁇ iodophenylJaminol-isonicotino- hydrazide:
- N'-(7-chloroquinolin-4-yl)-3-[(2-fluoro-4-iodophenyl)amino]isonicotino-hydrazide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.33 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicot ⁇ nic acid (intermediate 1) and 0.50 mmol of 7-chloroquinolin-4-yl-hydrazine.
- LC/MS [7.69 rnin; 534 (M + 1)]
- N-(cyclobutyl)-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1, outlined above, starting with 0.34 mmol of 3-[(2-fluoro- 4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.42 mmol of cyclobutylamine.
- LC/MS [9.86 min; 412 (M + 1)]
- N-(2,3-dihydro-1H-inden-1-yl)-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1, outlined above, starting with 0.43 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1 ) and 0.57 mmol of indanylamine. LC/MS [10.69 min; 474 (M + 1)]
- N-cyclope ⁇ tyl-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1, outlined above, starting with 0.45 mmol of 3-[(2-fluoro- 4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.57 mmol of cyclopentylamine.
- LC/MS [9.55 min; 426 (M + 1)]
- N-cyclohexyl-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1, outlined above, starting with 0.33 mmol of 3-[(2-fluoro- 4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.42 mmol of cyclohexylamine.
- LC/MS [10.52 min; 440 (M + 1)]
- N-(1 ,2-dimethylpropyl)-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.4 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.6 mmol of 2,3,dimethyl butylamine LC/MS [10.32 min; 428 (M + 1)]
- N-(2-Acetylamino-ethyl)-3-(2-chloro-4-iodo-phenylarnino)-isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.32 mmol of 3-[(2-chloro-4-iodophenyl)amino]isonicotinic acid (intermediate 2) and 0.44 mmol N-(2- amino-ethyl)-acetamidel_C/MS [8.38 min; 4.59 (M + 1)]
- Example 65 3-(2-Chloro-4-iodo-phenylamino)-pyridine-4-carbonyl]-carbamic acid tert- butyl ester:
- Example 72 2-Bromo-5-(2-fluoro-4-iodo-phenylamino)-N-(3-imidazol-1 -yl-propyl)- isonicotinamide:
- Example 75 N- ⁇ [(2S)-2,3-dihydroxypropyl]oxy ⁇ -3-[(2-fluoro-4-iodophenyl)- amino]isonicotin-amide:
- N-ethoxy-3-(4-iodo-phenylamino)-isonicotinamid e was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.30 mmol of 3-[(2-chloro-4- iodophenyl)amino]isonicotinic acid (intermediate 2) and 0.40 mmol of O-ethyl-hydroxylamine LC/MS [9.14 min; 418 (M + 1)]
- N-allyloxy-3-(2-chloro-4-iodo-phenylamino)-isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.20 mmol of 3-[(2-chloro-4- iodophenyl)amino]isonicotinic acid (intermediate 2) and 0.36 mmol of O-allyl-hydroxylam ine.
- LC/MS [9.30 min; 430 (M + 1)]
- N-isopropoxy-3-(2-chloro-4-iodo-phenylamino)-isonicotinamide was synthesized according to the procedure for General Method 1, outlined above, starting with 0.30 mmol of 3-[(2-chloro- 4-iodophenyl)amino]isonicotinic acid (intermediate 2) and 0.42 mmol of O-lsobutyl- hydroxylamine.
- LC/MS [10.06 min; 446 (M + 1)]
- N-(3-chloropropyl)-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 1 mmol of 3- [(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 1.3 mmol of 3- chloropropylamine.
- LC/MS [9.24 min; 434 (M + 1 )]
- Example 80 N-methoxy-3-(2-chloro-4-iodo-phienylamino)-isonicotinamide:
- N-methoxy-3-(2-chloro-4-iodo-phenylarnino)-ison icotinamide was synthesized according to the procedure for General Method 1, outlined above, starting with 0.30 mmol of 3-[(2-chloro- 4-iodophenyl)amino]isonicotinic acid (intermediate 2) and 0.42 mmol of O-methyl- hydroxylamine.
- LC/MS [8.75 min; 404 (M + 1)]
- N-Benzyloxy-3-(2-chloro-4-iodo-phenylamino)-isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.25 mmol of 3-[(2-chloro- 4-iodophenyl)amino]isonicotinic acid (intermediate 2) and 0.36 mmol of O-methyl- hydroxylamine.
- LC/MS [10.01 min; 480 (M + 1)]
- N-bicyclo[2.2.1]hept-2-yl-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.31 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.45 mmol of bicyclo[2.2.1]hept-2-ylamine. LC/MS [10.01 min; 452 (M + 1)]
- Example 84 3-[(2-fluoro-4-iodophenyl)amino]-N-(tetrahydro-2H-pyran-2-yloxy)- isonicotin-amide:
- N-(2,2-Dimethyl-[1 ,3]dioxolan-4-ylmethoxy)-3-(2-fluoro-4-iodo-phenylamino)-1-oxy- isonicotinamide was synthesized as described in General Method 2: to a solution of 3-(2- Fluoro-4-iodo-phenylamino)-1-oxy-isonicotinic acid (110 mg ,0.29mmol) in DMF (1.2 ml) was added 1,T-carbonylbis(1 H-imidazole) (52.45mg ,0.32 mmol). The reaction mixture was stirred at RT under argon for ⁇ hrs.
- Example 90 3-[(2-fluoro-4-iodophenyl)amino]-N'-(3-methylphenyl)isonicotino- hydrazide:
- N-(benzyloxy)-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1, outlined above, starting with 0.5 mmol of 3-[(2-fluoro-4- iodophenyl)amino]isonicotinic acid (intermediate 1 ) and 0.72 mmol of O-benzyl- hydroxylamine.
- LC/MS [9.50 min; 464 (M + 1)]
- N-(2,4-difluorobenzyl)-3-[(2-fluoro-4-iodophenyl)arnino]isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.33 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.49 mmol of 2,4- difluorobenzylamine.
- LC/MS [6.28 min; 484 (M + 1)]
- N-(2,2-diethoxyethyl)-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.33 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.5 mmol of 2,2- diethoxy-ethylamine.
- LC/MS [5.51 min; 474 (M + 1)]
- Example 101 N'-[3,5-bis(trifluoromethyl)phenyl]-3-[(2-fluoroiodophenyl)amino]- isonicotino-hydrazide:
- N'-[3,5-bis(trifluoromethyl)phenyl]-3-[(2-fluoroiodophenyl)amino]isonicotino-hydrazide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.37 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.53 mmol of 3,5-ditrifluoromethylbenzylhydrazine.
- LC/MS [6.47 min; 585 (M + 1)]
- Example 102 4-[2-( ⁇ 3-[(2-fluoro-4-iodophenyl)amino]isonicotinoyl ⁇ - amino)ethyl]benzoic acid:
- Example 104 3-[(2-fluoro-4-iodophenyl)am ⁇ no]-N-(3-methoxyphenyl)-isonicotinamide:
- Example 105 3-[(2-fluoro-4-iodophenyl)amino]-N-[3-fluoro-5-(trifluoromethyl)- benzy ⁇ sonicotinamide:
- Example 106 3-[(2-fluoro-4-iodophenyl)arnino]-N-(3-hydroxybenzyl)-isonicotina mide:
- N-(2,2-diethoxybutyl)-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.30 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.45 mmol of 2,2- dibutyloxy-ethylamine. LC/MS [6.33 min; 502 (M + 1)]
- N-(4-Fluoro-benzyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.25 mimol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.33 mmol of 4-fluoro- benzylamine. LC/MS [6.99 min; 466 (M + 1)]
- Example 110 3-(2-Fluoro-4-iodo-phenylamino)-IM-(1-hydroxymethyl-cyclo-pentyl)- isonicotinamide:
- 3-(2-Fluoro-4-iodo-phenylamino)-N-(1-hydroxymethyl-cyclopentyl)-isonicotinamide was synthesized according to the procedure for General Method 1, outlined above, starting with 0.25 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.42 mmol of. 1-amino-cyclopentyl)-methanol. LC/MS [6.04 min; 456 (M+1)].
- Example 112 N-(1-(S)-Carbamoyl-2-hydroxy-ethyl)-3-(2-fluoro-4-iodo-phenylamino)- isonicotinamide:
- N-(1-(S)-Carbamoyl-2-hydroxy-ethyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.30 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.45 mmol of L-serinamide.
- LC/MS [5.09 min; 445 (IVI + 1)]
- Example 114 N-(1,1-Bis-hydroxymethyl-propyl)-3-(2-fluoro-4-iodo-phenyl-amino)- isonicotin-amide :
- N-(1 , 1 -Bis-hydroxymethyl-propyl)-3-(2-fluoro-4- iodo-phenylamino)-isonicotinamide was synthesized according to the procedure for General Method 1, outlined above, starting with 0.33 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.47 mmol of 2-amino-2-ethyl-propane-1 ,3-diol.
- LC/MS [5.93 min; 460 (M + 1)]
- Example 115 l ⁇ l-(2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)- isonicotinamide:
- N-(2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide was synthesized according to the procedure for General Method 1 , outlined above, starting with 0.56 mmol of 3-[(2-fluoro-4-iodophenyl)amino]isonicotinic acid (intermediate 1) and 0.84 mmol of 2-amino- 2-ethyl-propane-1,3-diol.
- Step 1 Synthesis of 3-[(4-Bromo-2-fluoro)amino]isonicotinic acid.
- Step 2 3-[(4-Bromo-2-fluoro)amino]isonicotinic acid from step 1 (300mg, 0.964mmol) was dissolved in 6ml dry DMF followed by the addition of DIPEA (1.16mmol, 208 ⁇ l), PyBOP (1.16mmol, 602mg) and O-ethylhydroxylamine hydrochloride (1.93mmol, 188mg). The mixture was stirred at ambient temperature over night and the volatiles were removed in vacuo.
- Step 1 Synthesis of 3-[(4-iodo-2-fluoro)amino]isonicotinic acid.
- 3-Fluoro-isonicotinic acid (1g, 7.09mmol) and 4-iodo-2-fluoroaniline (1.68g, 7.09mmol) was added to 10mI of dry THF and the mixture was cooled to -78°C.
- LiHMDS (1 M in THF, 24.8ml) was added and the mixture was al lowed to warm to room temperature over night.
- Solid ammonium hydrochloride (2g) was added and after 1h the mixture was filtered and the volatiles were removed in vacuo.
- Step 2 3-[(4-lodo-2-fluoro)amino]isonicotinic acid from step 1 (200mg, 0.559mmol) was dissolved in 4ml dry DMF followed by the addition of DIPEA (0.671 mmol, 121 ⁇ l), PyBOP (0.371 mmol, 350mg) and O-ethylhydroxylamine hydrochloride (1.12mmol, 110mg). The mixture was stirred at ambient temperature over night and the volatiles were removed in vacuo. The crude material was purified by preparative RP-HPLC to give 113mg (282mmol; 50% yield) of the pure title compound] .
- Step 1 Synthesis of 3-(4-Bromo-2-fluoro-phenylamino)-isonicotinic acid hydrazide.
- Step 2 The material derived from step 1 was dissolved in DMF, DIPEA (1.14ml, 6.52mmol) and 1 ,1 ' -carbonyldiimidazole (CDI, 945mg, 5.83mmol) were aded and the mixture was stirred at room temperature for 14h. The volatiles were evaporated and the crude material was purified by flash-chromatography using a gradient of 30-80% ethyl acetate in cyclohexane to give 888mg (2.53mmol, 52%yield, 2 steps) of the title compound.
- LC-MS (method V): rt 3.27min; m/z [M+H]+ 351/353.
- Step 1 5-[3-(4-Bromo-2-fluoro-phenylamino)-pyridin-4-yl]-3H-[1 ,3,4]oxadiazol-2-one (example 19, 100mg, 0.277mmol) was dissolved in ethanol (4ml), ethanolamine (85rng, 1.38mmol) was added and the mixture was stirred for 20min at 16O 0 C in a microwave oven. The volatiles were removed to give the crude compound, which was used in the next step.
- Step 2 Dry dichloromethane (10ml) was added to the product derived from step 1, triphenylphosphine (113mg, 0.429mmol), triethylamine (58 ⁇ l, 0.416mmol) and carbon tetrachloride (107 ⁇ l, 1.11 mmol) were added. The mixture was heated at 100 0 C for 10>min in a microwave oven, the volatiles were removed and the crude material was purified by preparative HPLC to give 43mg (40 ⁇ yJeId) of the title compound.
- Example 128 N- ⁇ 5-[3-(4-Bromo-2-fluoro-phenylamino)-pyridin-4-yl]- [1 ,3,4]oxadiazol-2-yl ⁇ -N'-methyl-ettiane-1 ,2-diamine
- Step 1 5-[3-(4-Bromo-2-fluoro-phenylamino)-pyridin-4-yl]-3H-[1 ,3,4]oxadiazol-2-one (example 19, 100mg, 0.277mmol) was dissolved in ethanol (3ml), N-(2-aminoethyl)-N - methylcarbamic acid ⁇ -butylester (96rng, 0.554mmol) was added and the mixture was stirred for20min at 150 0 C in a microwave oven. The volatiles were removed to give the crude compound, which was used in the next step.
- Step 2 Dry dichloromethane (5ml) was added to the product derived from step 1 followed by triphenylphosphine (113rng, 0.429mmol), triethylamine (58 ⁇ l, 0.416mmol) and carbon tetrachloride (107 ⁇ l, 1.11 mmol). The mixture was heated at 100 0 C for20min in a microwave oven, the volatiles were removed and the crude material was purified by preparative HPLC to give 87mg (62°/ ⁇ yield) of the Boc-protected title compound. The material was treated with 4N HCI in dioxane (4ml) for 1h at ambient temperature and the volatiles were removed to give the pure title compound.
- Step 1 3-(4-Bromo-2-methyl-phenylamino)-isonicotinic acid hydrazide was prepared from 3-[(4-bromo-2-methylphenyl)amino]isonicotinic acid (example 2) by the procedure as described for example 126 step!
- Step 2 3-(4-Bromo-2-methyl-phenylamino)-isonicotinic acid hydrazide (0.426mmol) was dissolved in 5ml THF and treated with allylisocyanate (110mg, 0.852mmol) followed by DIPEA (110mg, 0.852mmol) and the mixture was stirred for 2h at ambient temperature. The volatiles were removed to give the crude compound, wich was used for the next step.
- Step 3 The product derived from step 2 was cyclized by the procedure described for example 127 step 2.
- LC-MS (method III): rt 6.99min; m/z [M+H]+ 386/388.
- the activity of the compounds of the present invitation may be determined by the following procedure: Inhibition of human MEK1 kinase activity was monitored with a homogenous, fluorescence based assay.
- the assay uses time resolved fluorescence resonance energy transfer to probe for phosphorylation of ERK1 by MEK1.
- the assay is carried out in low volume 96 well microtiterplates. In a total volume of 15 ⁇ l, compounds are incubated with 10OnM MEK1 , 15 ⁇ M ATP, 30OnM ERK2 employing a buffer containing 2OmM TRIS/HCI, 10 mM MgCI2, 100 ⁇ M NaVO4, 1 mM DTT, and 0.005% Tween 20 (pH 7.4).
- Assay 2 Tumor cell proliferation assays (ATP Lite)
- Murine colon C26, human melanoma A375 and Mel5 or human pancreatic MiaPaCa-2 cells were plated in 96 well Coming white plates (1500 cells/well for C26, and 2000 cells/well for A375, and MiaPaCa-2) and cultured overnight at 37 0 C in 5% CO2.
- Inhibitors were serially diluted in 100 % DMSO and subsequently added to cells to reach a final concentration of 0.25% DMSO. The cells were incubated for 4 days in the presence of test compounds in cell growth media (DMEM with 10% fetal bovine serum, 2mM glutamine for C26, and MiaPaCa-2, and RPMI with 10% fetal bovine serum, 2mM glutamine for A375).
- HBM, RLM and MLM Compounds were tested on their stability in human, rat and mouse liver microsomal preparations (HLM, RLM and MLM respectively). At a final concentration of 3 ⁇ M, compounds were incubated at 37°C with 0.5 mg/ml human, rat or mouse liver microsomes in a buffer containing 50 mM phosphate, pH 7.4 and 2 mM NADPH. Pooled human liver microsomes or pooled male rat liver microsomes (Sprague Dawley) were obtained from NatuTec (Frankfurt, Germany). Incubations without NADPH served as negative controls.
- Caco-2 cells obtained from the ATCC at passage number 27 are used.
- Cells (passage number 40-60) were seeded on to Millipore Multiscreen Caco-2 plates or Falcon HTS inserts at 1 x 105 cells/cm2.
- Cells were cultured for 20 days in DMEM and media was changed every two or three days. On day 20 the permeability study was performed.
- HBSS Hanks Balanced Salt Solution
- the monolayers were prepared by rinsing both basolateral and apical surfaces twice with HBSS at 37 0 C. Cells were then incubated with HBSS in both apical and basolateral compartments for 40 minutes to stabilize physiological parameters.
- HBSS was then removed from the apical compartment and replaced with test compound dosing solutions.
- the solutions were made by diluting 1OmM DMSO concentrates with HBSS to give a final test compound concentration of 10 ⁇ M (final DMSO concentration adjusted to 1%).
- the fluorescent integrity marker lucifer yellow was also included in the dosing solution.
- Analytical standards were made from dosing solutions. Test compound permeability was assessed in duplicate. On each plate compounds of known permeability characteristics were run as controls.
- apical compartment inserts were then placed into 'companion' plates containing fresh HBSS.
- B-A basolateral to apical
- the experiment was initiated by replacing buffer in the inserts then placing them in companion plates containing dosing solutions.
- the companion plate was removed and apical and basolateral samples diluted for analysis by LC-MS/MS (the donor compartment was also sampled to permit determination of starting concentration after non-specific binding has occurred).
- dQ/dt is the rate of permeation of the drug across the cells
- C 0 is the donor compartment concentration at time zero and A is the area of the cell monolayer.
- C 0 is obtained from analysis of the donor compartment at the end of the incubation period.
- Test compounds were grouped into low, medium or high absorption potential based on comparison with control compounds, which have known human absorption.
- Results are shown in Table 2. Wherein "+” means a caco A-B and caco B-A value of 1-10 and “++”means a caco A-B and caco B-A value of 11-100.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Photoreceptors In Electrophotography (AREA)
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0518192A BRPI0518192B8 (en) | 2004-10-20 | 2005-10-19 | 3-arylamino pyridine derivatives, their use and manufacturing process, and pharmaceutical composition |
DK05795030.5T DK1802579T3 (en) | 2004-10-20 | 2005-10-19 | Derivatives of 3-arylaminopyridine |
AU2005298932A AU2005298932B2 (en) | 2004-10-20 | 2005-10-19 | 3-arylamino pyridine derivatives |
CA2582247A CA2582247C (en) | 2004-10-20 | 2005-10-19 | 3-arylamino pyridine derivatives |
SI200531826T SI1802579T1 (en) | 2004-10-20 | 2005-10-19 | Derivatives of 3-arylaminopyridine |
ES05795030.5T ES2444866T3 (en) | 2004-10-20 | 2005-10-19 | 3-arylamino pyridine derivatives |
PL05795030T PL1802579T3 (en) | 2004-10-20 | 2005-10-19 | Derivatives of 3-arylaminopyridine |
US11/665,651 US7956191B2 (en) | 2004-10-20 | 2005-10-19 | 3-arylamino pyridine derivatives |
EA200700902A EA013212B1 (en) | 2004-10-20 | 2005-10-19 | 3-arylamino pyridine derivatives |
EP05795030.5A EP1802579B1 (en) | 2004-10-20 | 2005-10-19 | Derivatives of 3-arylaminopyridine |
JP2007537205A JP5214971B2 (en) | 2004-10-20 | 2005-10-19 | 3-allylaminopiperidine derivatives |
MX2007004781A MX2007004781A (en) | 2004-10-20 | 2005-10-19 | 3-arylamino pyridine derivatives. |
KR1020077011310A KR101318012B1 (en) | 2004-10-20 | 2005-10-19 | 3-arylamino pyridine derivatives |
CN200580040688.5A CN101065358B (en) | 2004-10-20 | 2005-10-19 | 3-arylamino pyridine derivatives |
NO20072595A NO339639B1 (en) | 2004-10-20 | 2007-05-21 | 3 arylaminopyridinderivater |
HK08101073.0A HK1107347A1 (en) | 2004-10-20 | 2008-01-28 | 3-arylamino pyridine derivatives 3- |
US13/112,490 US8198457B2 (en) | 2004-10-20 | 2011-05-20 | 3-arylamino pyridine derivatives |
US13/472,721 US8524911B2 (en) | 2004-10-20 | 2012-05-16 | 3-arylamino pyridine derivatives |
US13/940,065 US8841459B2 (en) | 2004-10-20 | 2013-07-11 | 3-arylamino pyridine derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04024967 | 2004-10-20 | ||
EP04024967.4 | 2004-10-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/665,651 A-371-Of-International US7956191B2 (en) | 2004-10-20 | 2005-10-19 | 3-arylamino pyridine derivatives |
US13/112,490 Division US8198457B2 (en) | 2004-10-20 | 2011-05-20 | 3-arylamino pyridine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006045514A1 true WO2006045514A1 (en) | 2006-05-04 |
Family
ID=34927054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/011257 WO2006045514A1 (en) | 2004-10-20 | 2005-10-19 | 3-arylamino pyridine derivatives |
Country Status (22)
Country | Link |
---|---|
US (4) | US7956191B2 (en) |
EP (1) | EP1802579B1 (en) |
JP (1) | JP5214971B2 (en) |
KR (1) | KR101318012B1 (en) |
CN (1) | CN101065358B (en) |
AR (1) | AR051248A1 (en) |
AU (1) | AU2005298932B2 (en) |
BR (1) | BRPI0518192B8 (en) |
CA (1) | CA2582247C (en) |
CY (1) | CY1114861T1 (en) |
DK (1) | DK1802579T3 (en) |
EA (1) | EA013212B1 (en) |
ES (1) | ES2444866T3 (en) |
HK (1) | HK1107347A1 (en) |
MX (1) | MX2007004781A (en) |
NO (1) | NO339639B1 (en) |
PL (1) | PL1802579T3 (en) |
PT (1) | PT1802579E (en) |
SI (1) | SI1802579T1 (en) |
UA (1) | UA94571C2 (en) |
WO (1) | WO2006045514A1 (en) |
ZA (1) | ZA200703912B (en) |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007044515A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
WO2007123936A1 (en) * | 2006-04-19 | 2007-11-01 | Laboratoires Serono Sa | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors |
WO2008021389A2 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
WO2010017051A1 (en) * | 2008-08-04 | 2010-02-11 | Merck Serono S.A. | Novel phenylamino isonicotinamide compounds |
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
WO2010078867A1 (en) * | 2009-01-09 | 2010-07-15 | Christian-Albrechts-Universität Zu Kiel | Method for improved bioactivation of medications |
WO2011019678A1 (en) * | 2009-08-11 | 2011-02-17 | Allergan, Inc. | Isothiozoles for treating conditions of the eye |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
WO2012007500A2 (en) | 2010-07-15 | 2012-01-19 | Bayer Cropscience Ag | New heterocyclic compounds as pesticides |
WO2012007883A1 (en) * | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
RU2469024C2 (en) * | 2006-12-22 | 2012-12-10 | Альмираль, С.А. | Aminonicotinic acid and isonicotinic acid derivatives as dhodg (dihydroorotate dehydrogenase) inhibitors |
WO2013152165A1 (en) | 2012-04-06 | 2013-10-10 | Sanofi | Methods for treating cancer using pi3k inhibitor and mek inhibitor |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
US8592629B2 (en) | 2010-07-12 | 2013-11-26 | Pfizer Limited | Sulfonamide derivatives as Nav 1.7 inhibitors |
WO2013178320A1 (en) | 2012-05-30 | 2013-12-05 | Merck Patent Gmbh | Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide |
WO2014040969A1 (en) | 2012-09-13 | 2014-03-20 | F. Hoffmann-La Roche Ag | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders |
US8772293B2 (en) | 2010-07-09 | 2014-07-08 | Pfizer Limited | Chemical compounds |
US8772343B2 (en) | 2010-07-12 | 2014-07-08 | Pfizer Limited | Chemical compounds |
EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
WO2014133071A1 (en) | 2013-02-27 | 2014-09-04 | 第一三共株式会社 | Method for predicting responsiveness to compound inhibiting mapk signal transduction pathway |
US9096500B2 (en) | 2010-07-12 | 2015-08-04 | Pfizer Limited | Acyl sulfonamide compounds |
US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
WO2019183385A1 (en) * | 2018-03-22 | 2019-09-26 | University Of Rochester | Mapk/erk inhibition for ovarian and other cancers |
WO2020130125A1 (en) | 2018-12-21 | 2020-06-25 | 第一三共株式会社 | Combination of antibody-drug conjugate and kinase inhibitor |
US10793541B2 (en) | 2012-10-12 | 2020-10-06 | Exelixis, Inc. | Process for making compounds for use in the treatment of cancer |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
CN113473978A (en) * | 2018-11-20 | 2021-10-01 | 恩福莱克逊治疗有限公司 | Cyanoarene-aniline compounds for the treatment of skin diseases |
WO2021206167A1 (en) | 2020-04-10 | 2021-10-14 | 大鵬薬品工業株式会社 | Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor |
WO2022101459A1 (en) | 2020-11-16 | 2022-05-19 | Merck Patent Gmbh | Kinase inhibitor combinations for cancer treatment |
WO2022133040A1 (en) * | 2020-12-16 | 2022-06-23 | Abm Therapeutics Corporation | Kinase inhibitors and uses thereof |
WO2022207479A1 (en) | 2021-03-27 | 2022-10-06 | Syngenta Crop Protection Ag | Microbiocidal isonicotinic amide derivatives |
WO2023089049A2 (en) | 2021-11-19 | 2023-05-25 | Syngenta Crop Protection Ag | Microbiocidal isonicotinic amide derivatives |
WO2023168203A1 (en) | 2022-03-04 | 2023-09-07 | Kinnate Biopharma Inc. | Inhibitors of mek kinase |
US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
TWI835048B (en) * | 2011-08-01 | 2024-03-11 | 美商建南德克公司 | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
US11975002B2 (en) | 2016-03-04 | 2024-05-07 | Taiho Pharmaceutical Co., Ltd. | Preparation and composition for treatment of malignant tumors |
WO2024132901A1 (en) | 2022-12-19 | 2024-06-27 | Syngenta Crop Protection Ag | Microbiocidal pyridazine dihydrooxadiazine derivatives |
WO2024143336A1 (en) * | 2022-12-28 | 2024-07-04 | 日本曹達株式会社 | Hydrazide compound and agricultural/horticultural bactericidal agent |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2582247C (en) | 2004-10-20 | 2014-02-11 | Applied Research Systems Ars Holding N.V. | 3-arylamino pyridine derivatives |
WO2007123939A2 (en) * | 2006-04-19 | 2007-11-01 | Laboratoires Serono S.A. | Novel arylamino n-heteraryls as mek inhibitors |
CN102718702B (en) * | 2011-03-31 | 2015-01-07 | 中国人民解放军军事医学科学院毒物药物研究所 | Aminopyridine derivatives and application thereof |
CN104870422B (en) | 2012-10-31 | 2019-03-15 | 富士胶片富山化学株式会社 | Amine derivative or its salt |
CN104788365B (en) * | 2014-01-16 | 2018-08-10 | 上海艾力斯医药科技有限公司 | Pyrazinamide derivative, preparation method and application |
US10179132B2 (en) | 2015-05-26 | 2019-01-15 | Industry-Academic Cooperation Foundation, Yonsei University | Composition for inducing differentiation of multipotent neural stem cells into dopaminergic neurons and method for inducing differentiation of multipotent neural stem cells into dopaminergic neurons by using the same |
KR20160138756A (en) * | 2015-05-26 | 2016-12-06 | 연세대학교 산학협력단 | composition for inducing differentiation of multi-potent neural stem cell into dopaminergic meurons and method for inducing differentiation using the same |
AR105483A1 (en) | 2015-06-30 | 2017-10-11 | Exelixis Inc | CRYSTAL FUMARATE SALT OF (S) - [3,4-DIFLUORO-2- (2-FLUORO-4-IODOPHENYLAMINE) PHENYL] [3-HIDROXI-3- (PIPERIDIN-2-IL) AZETIDIN-1-IL] - METANONE |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
WO2018097628A2 (en) | 2016-11-25 | 2018-05-31 | 주식회사 샤인바이오 | Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same |
AU2018263921A1 (en) | 2017-05-03 | 2019-12-05 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
KR101833412B1 (en) | 2017-07-24 | 2018-02-28 | 연세대학교 산학협력단 | composition for inducing differentiation of multi-potent neural stem cell into dopaminergic meurons and method for inducing differentiation using the same |
CA3073543A1 (en) | 2017-08-21 | 2019-02-28 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
US11524943B1 (en) | 2017-12-06 | 2022-12-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
US11661403B2 (en) | 2018-05-16 | 2023-05-30 | Vivace Therapeutics, Inc. | Oxadiazole compounds |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999001421A1 (en) * | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
WO2000042029A1 (en) * | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
WO2001005391A2 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
WO2003077855A2 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
WO2003101988A2 (en) * | 2002-05-31 | 2003-12-11 | Bayer Pharmaceuticals Corporation | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62223173A (en) * | 1986-03-25 | 1987-10-01 | Otsuka Pharmaceut Factory Inc | Pyridylaminophenol derivative and production thereof |
US4959378A (en) * | 1989-10-24 | 1990-09-25 | Hoechst-Roussel Pharmaceuticals Inc. | Aminopyridinylaminophenol compounds useful as topical antiinflammatory agents for the treatment of skin disorders |
US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
UA73073C2 (en) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Substituted 3-cyan chinolines |
IL132840A (en) | 1997-07-01 | 2004-12-15 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and pharmaceutical compositions comprising them for use as mek inhibitors |
KR20010099877A (en) * | 1998-12-22 | 2001-11-09 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Combination Chemotherapy |
CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
AU2203700A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Benzoheterocycles and their use as mek inhibitors |
AU2201500A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
AU2483400A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | 4'heteroaryl diarylamines |
EP1144372B1 (en) | 1999-01-13 | 2005-11-30 | Warner-Lambert Company Llc | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
WO2001068619A1 (en) | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
WO2001090074A2 (en) | 2000-05-22 | 2001-11-29 | Leo Pharma A/S | BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
WO2002006213A2 (en) * | 2000-07-19 | 2002-01-24 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
US20030073832A1 (en) * | 2001-04-10 | 2003-04-17 | Havez Sophie Elisabeth | Novel aminophenyl ketone derivatives |
WO2003027101A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors |
JP4602667B2 (en) | 2001-10-23 | 2010-12-22 | メルク セローノ ソシエテ アノニム | Azole derivatives and pharmaceutical compositions containing the azole derivatives |
SG194238A1 (en) | 2002-03-13 | 2013-11-29 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
AU2003293376A1 (en) * | 2002-12-10 | 2004-06-30 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
WO2004091480A2 (en) * | 2003-04-09 | 2004-10-28 | Exelixis, Inc. | Tie-2 modulators and methods of use |
CA2582247C (en) | 2004-10-20 | 2014-02-11 | Applied Research Systems Ars Holding N.V. | 3-arylamino pyridine derivatives |
SI1934174T1 (en) * | 2005-10-07 | 2011-08-31 | Exelixis Inc | Azetidines as mek inhibitors for the treatment of proliferative diseases |
-
2005
- 2005-10-19 CA CA2582247A patent/CA2582247C/en active Active
- 2005-10-19 ES ES05795030.5T patent/ES2444866T3/en active Active
- 2005-10-19 UA UAA200704548A patent/UA94571C2/en unknown
- 2005-10-19 AR ARP050104369A patent/AR051248A1/en active IP Right Grant
- 2005-10-19 AU AU2005298932A patent/AU2005298932B2/en active Active
- 2005-10-19 EP EP05795030.5A patent/EP1802579B1/en active Active
- 2005-10-19 MX MX2007004781A patent/MX2007004781A/en active IP Right Grant
- 2005-10-19 JP JP2007537205A patent/JP5214971B2/en active Active
- 2005-10-19 BR BRPI0518192A patent/BRPI0518192B8/en active IP Right Grant
- 2005-10-19 US US11/665,651 patent/US7956191B2/en active Active
- 2005-10-19 EA EA200700902A patent/EA013212B1/en not_active IP Right Cessation
- 2005-10-19 PT PT57950305T patent/PT1802579E/en unknown
- 2005-10-19 KR KR1020077011310A patent/KR101318012B1/en active IP Right Grant
- 2005-10-19 SI SI200531826T patent/SI1802579T1/en unknown
- 2005-10-19 DK DK05795030.5T patent/DK1802579T3/en active
- 2005-10-19 WO PCT/EP2005/011257 patent/WO2006045514A1/en active Application Filing
- 2005-10-19 PL PL05795030T patent/PL1802579T3/en unknown
- 2005-10-19 ZA ZA200703912A patent/ZA200703912B/en unknown
- 2005-10-19 CN CN200580040688.5A patent/CN101065358B/en active Active
-
2007
- 2007-05-21 NO NO20072595A patent/NO339639B1/en unknown
-
2008
- 2008-01-28 HK HK08101073.0A patent/HK1107347A1/en unknown
-
2011
- 2011-05-20 US US13/112,490 patent/US8198457B2/en active Active
-
2012
- 2012-05-16 US US13/472,721 patent/US8524911B2/en active Active
-
2013
- 2013-07-11 US US13/940,065 patent/US8841459B2/en active Active
-
2014
- 2014-02-18 CY CY20141100121T patent/CY1114861T1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999001421A1 (en) * | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
WO2000042029A1 (en) * | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
WO2001005391A2 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
WO2003077855A2 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
WO2003101988A2 (en) * | 2002-05-31 | 2003-12-11 | Bayer Pharmaceuticals Corporation | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
Non-Patent Citations (6)
Title |
---|
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1985, XP002316816, retrieved from STN Database accession no. 1985:149069 * |
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1988, XP002316815, retrieved from STN Database accession no. 1988:590279 * |
M. H. SHERLOCK ET AL.: "Antiallergy agents. 1. Substituted 1,8-naphthyridin-2(1H)-ones as inhibitors of SRS-A release", JOURNAL OF MEDICINAL CHEMISTRY., vol. 31, 1988, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, pages 2108 - 2121, XP002316814 * |
N. A. ORLOVA ET AL.: "Reaction of polyfluoro-substituted pyridine- and naphthalenecarboxylic acids with bromomagnesylaniline", IZVESTIYA SIBIRSKOGO OTDELENIYA AKADEMII NAUK SSSR SERIYA KHIMICHESKIKH NAUK, no. 6, 1984, NOVOSIBIRSK, RU, pages 93 - 97 * |
P. ZHU ET AL.: "Studies of antimalarials: synthesis of derivatives of benzo[b][1,7]naphthyridine with aminophenol Mannich base", YIYAO GONGYE, vol. 19, no. 2, 1899, BEIJING, CN, pages 55 - 57 * |
THEOPHIL EICHER; SIEGFRIED HAUPTMANN: "The Chemistry of Heterocycles; Structures, Reactions, Synthesis and Application", 2003, WILEY-VCH |
Cited By (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8362002B2 (en) | 2005-10-07 | 2013-01-29 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US7915250B2 (en) | 2005-10-07 | 2011-03-29 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
WO2007044515A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
EA019983B1 (en) * | 2005-10-07 | 2014-07-30 | Экселиксис, Инк. | Mek inhibitors and methods of using same |
EA025871B1 (en) * | 2005-10-07 | 2017-02-28 | Экселиксис, Инк. | Mek inhibitors and methods of using the same |
CN109053523A (en) * | 2005-10-07 | 2018-12-21 | 埃克塞利希斯股份有限公司 | Azetidine as the mek inhibitor for treating proliferative disease |
US7803839B2 (en) | 2005-10-07 | 2010-09-28 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
EA032466B1 (en) * | 2005-10-07 | 2019-05-31 | Экселиксис, Инк. | Methods of making mek inhibitors |
CN109053523B (en) * | 2005-10-07 | 2022-03-25 | 埃克塞利希斯股份有限公司 | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US11597699B2 (en) | 2005-10-07 | 2023-03-07 | Exelixis, Inc. | MEK inhibitors and methods of their use |
JP2009534386A (en) * | 2006-04-19 | 2009-09-24 | ラボラトワール セローノ ソシエテ アノニム | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors |
CN103121996A (en) * | 2006-04-19 | 2013-05-29 | 默克雪兰诺有限公司 | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors |
US8076486B2 (en) | 2006-04-19 | 2011-12-13 | Merck Serono S.A. | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors |
CN103121996B (en) * | 2006-04-19 | 2015-10-21 | 默克雪兰诺有限公司 | As the arylamino pyridine derivatives that the heteroaryl of mek inhibitor replaces |
WO2007123936A1 (en) * | 2006-04-19 | 2007-11-01 | Laboratoires Serono Sa | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors |
AU2007284562B2 (en) * | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
WO2008021389A3 (en) * | 2006-08-16 | 2008-07-17 | Exelixis Inc | Using pi3k and mek modulators in treatments of cancer |
JP2013151570A (en) * | 2006-08-16 | 2013-08-08 | Exelixis Inc | Method of using pi3k and mek modulators |
US8642584B2 (en) | 2006-08-16 | 2014-02-04 | Exelixis, Inc. | Method of using PI3K and MEK modulators |
WO2008021389A2 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
CN104784695A (en) * | 2006-08-16 | 2015-07-22 | 埃克塞利希斯股份有限公司 | Method of using PI3K and MEK modulators |
JP2010500994A (en) * | 2006-08-16 | 2010-01-14 | エグゼリクシス, インコーポレイテッド | Methods of using PI3K and MEK modulators |
WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
AU2007334402B2 (en) * | 2006-12-14 | 2014-02-13 | Exelixis, Inc. | Methods of using MEK inhibitors |
CN105106199A (en) * | 2006-12-14 | 2015-12-02 | 埃克塞利希斯股份有限公司 | Methods of using MEK inhibitors |
US7999006B2 (en) | 2006-12-14 | 2011-08-16 | Exelixis, Inc. | Methods of using MEK inhibitors |
RU2469024C2 (en) * | 2006-12-22 | 2012-12-10 | Альмираль, С.А. | Aminonicotinic acid and isonicotinic acid derivatives as dhodg (dihydroorotate dehydrogenase) inhibitors |
WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
WO2008124085A3 (en) * | 2007-04-03 | 2010-04-15 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
US8404725B2 (en) | 2008-08-04 | 2013-03-26 | Merck Patent Gmbh | Phenylamino isonicotinamide compounds |
KR20110044768A (en) * | 2008-08-04 | 2011-04-29 | 메르크 파텐트 게엠베하 | Novel phenylamino isonicotinamide compounds |
EA018539B1 (en) * | 2008-08-04 | 2013-08-30 | Мерк Патент Гмбх | Phenylamino isonicotinamide compounds |
AU2009279940B2 (en) * | 2008-08-04 | 2014-01-16 | Merck Patent Gmbh | Novel phenylamino isonicotinamide compounds |
WO2010017051A1 (en) * | 2008-08-04 | 2010-02-11 | Merck Serono S.A. | Novel phenylamino isonicotinamide compounds |
US20110184032A1 (en) * | 2008-08-04 | 2011-07-28 | Merck Patent Gmbh | Novel Phenylamino Isonicotinamide Compounds |
KR101651700B1 (en) * | 2008-08-04 | 2016-08-26 | 메르크 파텐트 게엠베하 | Novel phenylamino isonicotinamide compounds |
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
WO2010078867A1 (en) * | 2009-01-09 | 2010-07-15 | Christian-Albrechts-Universität Zu Kiel | Method for improved bioactivation of medications |
AU2010204395B2 (en) * | 2009-01-09 | 2016-04-14 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Method for improved bioactivation of medications |
WO2011019678A1 (en) * | 2009-08-11 | 2011-02-17 | Allergan, Inc. | Isothiozoles for treating conditions of the eye |
US9279144B2 (en) | 2010-02-25 | 2016-03-08 | Dana-Farber Cancer Institute, Inc. | Screening method for BRAF inhibitors |
EP3028699A1 (en) | 2010-02-25 | 2016-06-08 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
US11078540B2 (en) | 2010-03-09 | 2021-08-03 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
US8772293B2 (en) | 2010-07-09 | 2014-07-08 | Pfizer Limited | Chemical compounds |
US8772343B2 (en) | 2010-07-12 | 2014-07-08 | Pfizer Limited | Chemical compounds |
WO2012007883A1 (en) * | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
US8685977B2 (en) | 2010-07-12 | 2014-04-01 | Pfizer Limited | Chemical compounds |
US9096500B2 (en) | 2010-07-12 | 2015-08-04 | Pfizer Limited | Acyl sulfonamide compounds |
US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
US8592629B2 (en) | 2010-07-12 | 2013-11-26 | Pfizer Limited | Sulfonamide derivatives as Nav 1.7 inhibitors |
WO2012007500A2 (en) | 2010-07-15 | 2012-01-19 | Bayer Cropscience Ag | New heterocyclic compounds as pesticides |
US9233951B2 (en) | 2010-07-15 | 2016-01-12 | Bayer Intellectual Property Gmbh | Heterocyclic compounds as pesticides |
WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
TWI835048B (en) * | 2011-08-01 | 2024-03-11 | 美商建南德克公司 | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
WO2013152165A1 (en) | 2012-04-06 | 2013-10-10 | Sanofi | Methods for treating cancer using pi3k inhibitor and mek inhibitor |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
WO2013178320A1 (en) | 2012-05-30 | 2013-12-05 | Merck Patent Gmbh | Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide |
TWI570108B (en) * | 2012-05-30 | 2017-02-11 | 馬克專利公司 | Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenyl amino)-isonicotinamide |
AU2013269994B2 (en) * | 2012-05-30 | 2017-04-20 | Merck Patent Gmbh | Solid state forms of N-((S)-2,3-Dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide |
EA028059B1 (en) * | 2012-05-30 | 2017-10-31 | Мерк Патент Гмбх | Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)isonicotinamide |
US9260393B2 (en) | 2012-05-30 | 2016-02-16 | Merck Patent Gmbh | Solid state forms of N-((S)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide |
WO2014040969A1 (en) | 2012-09-13 | 2014-03-20 | F. Hoffmann-La Roche Ag | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders |
US11414396B2 (en) | 2012-10-12 | 2022-08-16 | Exelixis, Inc. | Process for making compounds for use in the treatment of cancer |
US10793541B2 (en) | 2012-10-12 | 2020-10-06 | Exelixis, Inc. | Process for making compounds for use in the treatment of cancer |
EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
WO2014107713A1 (en) * | 2013-01-07 | 2014-07-10 | Sanofi | Combination of a hdm2 antagonist and a mek inhibitor for use in treating cancer |
US10139415B2 (en) | 2013-02-27 | 2018-11-27 | Daiichi Sankyo Company, Limited | Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway |
WO2014133071A1 (en) | 2013-02-27 | 2014-09-04 | 第一三共株式会社 | Method for predicting responsiveness to compound inhibiting mapk signal transduction pathway |
US11975002B2 (en) | 2016-03-04 | 2024-05-07 | Taiho Pharmaceutical Co., Ltd. | Preparation and composition for treatment of malignant tumors |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
WO2019183385A1 (en) * | 2018-03-22 | 2019-09-26 | University Of Rochester | Mapk/erk inhibition for ovarian and other cancers |
CN113473978A (en) * | 2018-11-20 | 2021-10-01 | 恩福莱克逊治疗有限公司 | Cyanoarene-aniline compounds for the treatment of skin diseases |
US11572344B2 (en) | 2018-11-20 | 2023-02-07 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
EP3883552A4 (en) * | 2018-11-20 | 2022-08-17 | NFlection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
WO2020130125A1 (en) | 2018-12-21 | 2020-06-25 | 第一三共株式会社 | Combination of antibody-drug conjugate and kinase inhibitor |
WO2021206167A1 (en) | 2020-04-10 | 2021-10-14 | 大鵬薬品工業株式会社 | Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor |
WO2022101459A1 (en) | 2020-11-16 | 2022-05-19 | Merck Patent Gmbh | Kinase inhibitor combinations for cancer treatment |
WO2022133040A1 (en) * | 2020-12-16 | 2022-06-23 | Abm Therapeutics Corporation | Kinase inhibitors and uses thereof |
WO2022207479A1 (en) | 2021-03-27 | 2022-10-06 | Syngenta Crop Protection Ag | Microbiocidal isonicotinic amide derivatives |
WO2023089049A2 (en) | 2021-11-19 | 2023-05-25 | Syngenta Crop Protection Ag | Microbiocidal isonicotinic amide derivatives |
US11780862B2 (en) | 2022-03-04 | 2023-10-10 | Kinnate Biopharma Inc. | Inhibitors of MEK kinase |
WO2023168203A1 (en) | 2022-03-04 | 2023-09-07 | Kinnate Biopharma Inc. | Inhibitors of mek kinase |
WO2024132901A1 (en) | 2022-12-19 | 2024-06-27 | Syngenta Crop Protection Ag | Microbiocidal pyridazine dihydrooxadiazine derivatives |
WO2024143336A1 (en) * | 2022-12-28 | 2024-07-04 | 日本曹達株式会社 | Hydrazide compound and agricultural/horticultural bactericidal agent |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1802579B1 (en) | Derivatives of 3-arylaminopyridine | |
EP1828184B1 (en) | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases | |
EP1838675A1 (en) | Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders | |
DK2307376T3 (en) | NOVEL phenylamino ISONIKOTINAMIDFORBINDELSER | |
Deppe et al. | HAMILTON, BROOK, SMITH 4 REYNOLDS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV LY MD MG MK MN MW MX MZ NA NG NO NZ OM PG PH PL PT RO RU SC SD SG SK SL SM SY TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2582247 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005298932 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005795030 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2762/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 182600 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2005298932 Country of ref document: AU Date of ref document: 20051019 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/004781 Country of ref document: MX Ref document number: 2007537205 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005298932 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077011310 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200700902 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580040688.5 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005795030 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11665651 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0518192 Country of ref document: BR |